Document:

Exhibit 4.1

 

THE WARRANTS REPRESENTED BY THIS WARRANT CERTIFICATE
ARE TRANSFERABLE AND ASSIGNABLE SUBJECT TO COMPLIANCE WITH APPLICABLE SECURITIES LAWS. THE WARRANTS REPRESENTED BY THIS WARRANT CERTIFICATE
WILL BE VOID AND OF NO VALUE UNLESS EXERCISED ON OR BEFORE 5:00 P.M. (NEW YORK TIME) ON [●], 2027.

 

WARRANT
CERTIFICATE

 

ARMATA
PHARMACEUTICALS, Inc.

 

(Incorporated under the Laws of the State of Washington)

 

	[●] Warrants	Right to Purchase
	 	[●] Common Shares

 

WARRANTS
FOR PURCHASE OF COMMON SHARES

 

THIS
IS TO CERTIFY THAT, for value received, Innoviva Strategic Opportunities LLC, a Delaware limited liability company and a wholly-owned
subsidiary of Innoviva, Inc., a Delaware corporation (the “Holder”), is the holder of [●] common share purchase
warrants (the “Warrants”). Each Warrant entitles the Holder to subscribe for and purchase one fully paid and non-assessable
Common Share of Armata Pharmaceuticals, Inc. (the “Company”) at any time or times prior to 5:00 p.m. (New
York time) on [●], 2027 (the “Time of Expiry”) at the price of $5.00 per Common Share (the “Exercise
Price”), upon the terms and conditions set forth in this Warrant Certificate (this “Warrant Certificate”
or this “Warrant”). The number of Common Shares which the Holder is entitled to acquire upon exercise of a Warrant
and the Exercise Price are subject to adjustment in accordance with the terms and conditions hereof. Whether or not expressly set forth
herein, all amounts payable hereunder, including the Exercise Price if paid in cash, shall be paid in United States Dollars.

 

The Warrants represented by
this Warrant Certificate may be exercised by the Holder, in whole or in part or parts (but not as to a fractional share), by surrender
of this Warrant Certificate (properly endorsed) with the Subscription Form appended hereto as Schedule A or any other written
notice in a form reasonably satisfactory to the Company duly completed and executed by the Holder, at the office of the Company in accordance
with Section 12 hereof, together with the purchase price of such Common Shares as herein provided.

 

The Warrant Certificate and
such payment shall be deemed not to have been surrendered and made except upon personal delivery thereof or, if sent by post or other
means of transmission, upon actual receipt thereof by the Company at the office specified above.

 

Subject to Section 4,
the purchase price of Common Shares subscribed for hereunder shall be paid by certified check, money order, bank draft payable to or to
the order of the Company in lawful money of the United States of America or wire transfer of immediately available funds, or any combination
of the foregoing, in each case, in the discretion of the Holder.

 

     

     

    

 

In the event of any exercise
of the Warrants represented by this Warrant Certificate in accordance with the terms hereof, (a) Common Shares purchased hereunder
shall be transmitted by the Company’s transfer agent to the Holder by crediting the account of the Holder’s or its designee’s
balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”)
if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance
of the Common Shares to or resale of the Common Shares by the Holder or (B) the Common Shares are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144 (and the Holder has delivered a legal opinion in form and substance
reasonably acceptable to the Company to such effect), and otherwise (b) by physical delivery of certificates for the Common Shares
or confirmation of book entry issuance for the Common Shares (as may be directed by the Holder) so purchased will be delivered to the
Person(s) in whose name(s) the Common Shares so subscribed for are to be issued within two Business Days (“Warrant
Share Delivery Date”) of the exercise of the Warrants represented by this Warrant Certificate (or if the share transfer books
of the Company are properly closed, within two Business Days of the opening of said share transfer books), such Person(s) shall be
deemed for all corporate purposes to have become the holder of record of the Common Shares with respect to which this Warrant has been
exercised, irrespective of the date of delivery of the Warrant, provided that payment of the aggregate Exercise Price (other than in the
case of a cashless exercise) is received by the Company. Unless (i) this Warrant Certificate has expired or (ii) all of the
Warrants evidenced by this Warrant Certificate have been exercised, a new Warrant Certificate representing the unexercised balance of
the Warrants will also be issued to the Holder within such time at the expense of the Company.

 

If the Company fails for any
reason to deliver to the Holder the Common Shares subject to an exercise notice by the Warrant Share Delivery Date, the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Common Shares subject to such exercise (based
on the Current Market Price on the date of the applicable exercise notice), $5 per Trading Day (increasing to $10 per Trading Day on the
fifth (5th) Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date (subject
to receipt of the aggregate Exercise Price for the applicable exercise (other than in the case of a cashless exercise)) until such Common
Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the Depository
Trust Company Fast Automated Securities Transfer Program so long as this Warrant remains outstanding and exercisable. The payments contemplated
by this paragraph shall not limit a Holder’s right to pursue equitable remedies including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the such failure.

 

THE FOLLOWING ARE THE TERMS AND CONDITIONS
REFERRED TO IN THIS WARRANT CERTIFICATE:

 

Section 1     Definitions.

 

		(1)	In this Warrant Certificate, the following phrases and words have the respective meanings indicated opposite
them as follows:

 

“Affiliate” means,
as to any Person, any other Person that, directly or indirectly, is in control of, is controlled by, or is under common control with,
such first Person;

 

    - 2 -

     

    

 

“Applicable Securities Laws”
means, collectively, all applicable securities Laws in each of the jurisdictions in which the Warrants or Common Shares issued on the
exercise of Warrants are issued or acquired, and the respective regulations and rules under such Laws, together with applicable published
rules, policy statements, blanket orders, instruments, rulings and notices of the securities regulatory authorities in the jurisdictions
and all applicable rules and regulations of any exchange on which the Common Shares are listed for trading;

 

“Business Day” means
any day other than a Saturday, a Sunday or a day on which banks in the City of New York are authorized or obligated by Law or Order to
close;

 

“Common Shares” means
the shares of common stock of the Company, par value $0.01 per share and, in the event that there shall occur a change in respect of or
affecting the Common Shares referred to in Section 2 (whether or not such change shall result in an adjustment to the Exchange Basis
or the Exercise Price), the term “Common Shares” shall mean the shares, other securities or other property which the
Holder is entitled to purchase resulting from such change;

 

“control”
(including, with correlative meanings, the terms “controlled by” and “under common control with”), as applied
to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies
of such Person, whether through the ownership of voting securities or other ownership interests, by contract or otherwise;

 

“Current Market Price”
of a Common Share means, on any given date, the price per Common Share equal to the volume weighted average trading price of the Common
Shares on the Principal Securities Exchange (or, if the Common Shares are not listed and posted for trading on the Principal Securities
Exchange, such other stock exchange or over-the-counter market on which the Common Shares may be listed or quoted) for the immediately
preceding 20 consecutive Trading Days calculated by dividing the aggregate sale price of all such shares sold on such stock exchange during
such 20 day period by the total number of such shares so sold. If the Common Shares are not then traded on the Principal Securities Exchange,
an over-the-counter market or on a recognized exchange or market, the Current Market Price of a Common Share shall be the fair market
value of a Common Share as agreed to by the board of directors of the Company and the Holder, acting in good faith, and absent such agreement,
as determined by an independent valuation expert reasonably acceptable to both the Company and the Holder; provided, that the fair
market value determined by the independent valuation shall not be (a) higher than the highest fair market value proposed by the board
of directors of the Company or the Holder, or (b) lower than the lowest fair market value proposed by the board of directors of the
Company or the Holder. The Company shall be responsible for the costs and expenses of the valuation expert;

 

    - 3 -

     

    

 

“Exchange Basis”
means, as at any time, the number of Common Shares which the Holder is entitled to receive upon the exercise of a Warrant represented
by this Warrant Certificate and which, as at the date hereof, is equal to one Common Share per Warrant;

 

“Fundamental Transaction”
means that (A) the Company shall, directly or indirectly, in one or more related transactions, (i) consolidate or merge with
or into (whether or not the Company is the surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise
dispose of all or substantially all of the properties or assets of the Company to another Person, or (iii) allow another Person to
make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding Common Shares (not including
any Common Shares held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such
purchase, tender or exchange offer), or (iv) consummate a stock purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires
more than 50% of the outstanding Common Shares (not including any Common Shares held by the other Person or other Persons making or party
to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination),
or (v) reorganize, recapitalize or reclassify the Common Shares or (B) any “person” or “group” (as these
terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act) other than the Holder or any group to which the holder is a Member, directly or
indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding Common Shares.

 

“Governmental Authority”
means any federal, state, provincial or local court, legislature, executive or regulatory authority, agency, ministry, bureau or commission,
stock exchange or other governmental authority or instrumentality;

 

“Law” means any federal,
state, local or foreign law, common law, statute, ordinance, rule, regulation, code, treaty or Permit, in each case enacted, promulgated
or issued by a Governmental Authority;

 

“Liens” means any
lien, security interest, mortgage, pledge, charge or similar encumbrance;

 

“NYSE American” means
the New York Stock Exchange American.

 

“Order” means any
consent, approval, order, judgment, decree or authorization of any Governmental Authority;

 

“Permit” means any
registration, license, exemption, authorization, or permit of any Governmental Authority;

 

“Person” means an
individual, a corporation, a limited liability company, a partnership, an association, a trust or other entity or organization;

 

    - 4 -

     

    

 

“Principal Securities Exchange”
means any United States national stock exchange or automated inter-dealer quotation system upon which the Company has listed the Common
Shares for trading; as of the date hereof, the Principal Securities Exchange for the Common Shares is the NYSE American;

 

“Representatives”
of any Person means such Person’s directors, managers, officers, employees, agents, attorneys, accountants, consultants, professional
advisors or other representatives; and

 

“Successor Entity”
means the Person (or, if so elected by the Holder, the parent entity of such Person) formed by, resulting from or surviving any Fundamental
Transaction or the Person (or, if so elected by the Holder, the parent entity of such Person) with which such Fundamental Transaction
shall have been entered into.

 

“Trading Day” with
respect to any stock exchange (including the Principal Securities Exchange) or over-the-counter market means a day in which shares may
be traded through the facilities of such stock exchange or over-the-counter market.

 

		(2)	Whenever used in this Warrant, words importing the singular number only shall include the plural, and
vice versa, and words importing the masculine gender shall include the feminine gender.

 

		(3)	Unless otherwise specified, the word “Section” and other subdivision followed by a
number mean and refer to the specified Section or other subdivision of this Warrant Certificate. In the computation of periods of
time from a specified date to a later specified date, unless otherwise expressly stated, the word “from” means “from
and including” and the words “to” and “until” each mean “to but excluding”.
The words “hereof,” “herein,” “hereto,” “hereunder” and “hereinafter”
and words of similar import refer to this Warrant Certificate as a whole and not to any particular provision hereof; (ii) the character
 “$” shall mean United States Dollars; (iii) the word “including” shall mean “including,
without limitation,” and the words “include” and “includes” shall have corresponding meanings,
and such words shall not be construed to limit any general statement that they follow to the specific items or matters immediately following
them; (iv) the words “either,” “or,” “neither,” “nor”
and “any” are not exclusive; and (v) references to “days” shall refer to calendar days unless
Business Days are specified.

 

Section 2     Adjustments.

 

Subject to Section 3,
the Exercise Price and the Exchange Basis will be subject to adjustment from time to time in the events and in the manner provided as
follows:

 

		(a)	Common Share Reorganization. If and whenever, at any time after the date hereof and prior to the
Time of Expiry, the Company:

 

		(i)	issues Common Shares, or securities exchangeable for or convertible into Common Shares, to all or substantially
all the holders of the Common Shares as a stock dividend or other distribution payable in Common Shares or securities exercisable or exchangeable
for or convertible into Common Shares;

 

    - 5 -

     

    

   

		(ii)	subdivides, redivides or changes its then outstanding Common Shares into a greater number of shares; or

 

		(iii)	reduces, combines or consolidates its then outstanding Common Shares into a lesser number of shares,

 

(any of such events in these clauses
(i), (ii) or (iii) being called a “Common Share Reorganization”), then the Exchange Basis will be adjusted
effective immediately after the effective date of, or the record date at which the holders of Common Shares are determined for the purpose
of, the Common Share Reorganization, by multiplying the Exchange Basis in effect immediately prior to such effective date or record date
by a fraction:

 

		(A)	the numerator of which will be the number of Common Shares outstanding immediately after giving effect
to such Common Share Reorganization (including, in the case where securities exercisable or exchangeable for or convertible into Common
Shares are distributed, the number of Common Shares that would have been outstanding had such securities been exercised or exchanged for
or converted into Common Shares on such effective date or record date, assuming in any case where such securities are not then exercisable,
convertible or exchangeable but subsequently become so, that they were exercisable, convertible or exchangeable on the effective date
or record date on the basis upon which they first become exercisable, convertible or exchangeable); and

 

		(B)	the denominator of which will be the number of Common Shares outstanding on such effective date or record
date before giving effect to such Common Share Reorganization.

 

The resulting product, adjusted to the
nearest 1/100th, will thereafter be the Exchange Basis until further adjusted as provided in this Section 2.

 

		(b)	Distributions. If and whenever, at any time after the date hereof and prior to the Time of Expiry,
the Company will fix a record date for the distribution or dividend to all or substantially all the holders of the Common Shares of any
property or other assets (including any securities, rights, options, warrants or other securities of another person) other than
any dividend of cash, but including a distribution of evidences of indebtedness and provided that such distribution or dividend does not
constitute a Common Share Reorganization (any of such non-excluded events being herein called a “Distribution”), the
Exchange Basis will be adjusted effective immediately after the record date for the Distribution by multiplying the Exchange Basis in
effect on such record date by a fraction:

 

		(i)	the numerator of which shall be the product of the number of Common Shares outstanding on such record
date and the Current Market Price of the Common Shares on such record date; and

 

    - 6 -

     

    

 

		(ii)	the denominator of which shall be:

 

		(A)	an amount equal to the product (x) of the number of Common Shares outstanding on such record date
and (y) the Current Market Price of the Common Shares on such record date, less

 

		(B)	the fair market value on such record date, as determined by action by the directors of the Company, acting
reasonably and in good faith, of the property or other assets distributed or dividended in the Distribution; provided that no such adjustment
will be made if the result of such adjustment would be to decrease the Exchange Basis in effect immediately before such record date. The
resulting product, adjusted to the nearest 1/100th, will thereafter be the Exchange Basis until further adjusted as provided in this Section 2.

 

		(c)	Cash Distribution. If and whenever, at any time after the date hereof and prior to the Time of
Expiry, the Company will fix a record date for a distribution or dividend of cash to all or substantially all the holders of the Common
Shares, the Holder shall be entitled to participate in such distribution to the same extent that the Holder would have participated therein
if the Holder had exercised this Warrant in full immediately before the date of which a record is taken for such distribution, or, if
no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such distribution.

 

		(d)	Fundamental Transaction. At any time after the date hereof and prior to the Time of Expiry, upon
the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the
date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the
Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under
this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Fundamental
Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at
any time after the consummation of the Fundamental Transaction, in lieu of the Common Shares (or other securities, cash, assets or other
property purchasable upon the exercise of the Warrant prior to such Fundamental Transaction), such shares of stock, securities, cash,
assets or any other property whatsoever (including warrants or other purchase or subscription rights), if any, that the Holder would have
been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been exercised immediately prior to such
Fundamental Transaction, as adjusted in accordance with the provisions of this Warrant. In addition to and not in substitution for any
other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of Common Shares are entitled
to receive securities or other assets (including cash) with respect to or in exchange for Common Shares, the Company shall make appropriate
provision to ensure that the Holder will thereafter have the right to receive upon exercise of this Warrant within 10 days after the consummation
of the Fundamental Transaction but, in any event, prior to the Time of Expiry, in lieu of the Common Shares (or other securities, cash,
assets or other property) purchasable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities,
cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have
been entitled to receive upon the happening of such Fundamental Transaction had the Warrant been exercised immediately prior to such Fundamental
Transaction.

 

    - 7 -

     

    

 

		(e)	Any adjustment to the Exchange Basis pursuant to Section 2(a) including any readjustment, will
include a corresponding adjustment to the Exercise Price which will be calculated by multiplying the Exercise Price by a fraction: (i) the
numerator of which will be the Exchange Basis immediately prior to such adjustment, and (ii) the denominator of which will be the
Exchange Basis immediately following the adjustment.

 

		(f)	In the event the Company shall propose to take any action of the type described in this Section 2
(but only if the action of the type described in this Section 2 would result in an adjustment in the Exchange Basis or Exercise Price
or a change in the type of securities or property to be delivered upon exercise of this Warrant Certificate), the Company shall give notice
to the Holder at least 10 days prior to the record date in respect of such action (or the date of such action in the event that there
is no record date), in the manner set forth in Section 12, which notice shall specify the record date, if any, with respect to any
such action and the approximate date on which such action is to take place. Such notice shall also set forth the facts with respect thereto
as shall be reasonably necessary to indicate the effect on the Exchange Basis or Exercise Price or a change in the type of securities
or property to be delivered upon exercise of this Warrant Certificate.

 

		(g)	If and whenever, at any time after the date hereof and prior to the Time of Expiry and provided that this
Warrant has not been exercised, the Company shall make a distribution pursuant to Section 2(b) of the shares or other equity
interests of a subsidiary of the Company (the “Spin-off Entity”) in a “spin-off” or similar transaction,
then the Company (a) shall issue to the Holder a new warrant to purchase, at the Spin-off Entity Exercise Price (as defined below),
the number of shares of common stock or other equity interest in the Spin-off Entity (and any other consideration) that the Holder would
have owned had the Holder exercised or converted this Warrant immediately prior to the consummation of such spin-off and (b) shall
make provision therefor in the agreement, if any, relating to such spin-off. Such new warrant shall provide for rights and obligations
which shall be as nearly equivalent as may be practicable to the rights and obligations provided for in this Warrant. The provisions of
this Section 2(g) (and any equivalent thereof in any such new warrant) shall apply to successive transactions. For purposes
of this Section 2(g), the “Spin-off Entity Exercise Price” shall mean the amount by which the Exercise Price under
this Warrant was decreased with respect to the relevant distribution pursuant to the terms of Section 2(b).

 

    - 8 -

     

    

 

		(h)	In addition to any adjustments pursuant to Section 2 above and without limitation of the terms of
any other agreement or any rights in respect of issued and outstanding shares of Common Stock held by the Holder, if at any time prior
to the Time of Expiry the Company grants, issues or sells any options, convertible Securities or rights to purchase stock, warrants, securities
or other property pro rata to all or substantially all of the holders of Common Shares (the “Purchase Rights”), then
the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of Common Shares Stock acquirable upon complete exercise of this Warrant immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of Common Shares are to be determined for the grant, issue or sale of such Purchase Rights.

 

Section 3     Rules Regarding
Calculation of Adjustment of Exchange Basis.

 

For the purposes of Section 2:

 

		(a)	The adjustments provided for in Section 2 will be cumulative and will be made successively upon the
occurrence of an event described therein, subject to this Section 3. For greater certainty, if any action would require adjustment
pursuant to more than one of the provisions described in Section 2 in a manner such that such adjustments are duplicative, only one
adjustment shall be made.

 

		(b)	No adjustment in the Exchange Basis will be required unless such adjustment would result in a change to
the then prevailing Exchange Basis of at least 1% or of at least 1/100th of a Common Share based on the prevailing Exchange Basis, provided,
however, that any adjustments which, except for the provisions of this Section 3(b) would otherwise have been required to be
made, will be carried forward and taken into account in any subsequent adjustment.

 

		(c)	No adjustment in the Exchange Basis will be made pursuant to Section 2 in respect of the issuance
from time to time of:

 

		(i)	Common Shares purchasable on exercise of the Warrants; or

 

		(ii)	Common Shares pursuant to any stock options, stock option plan, stock purchase plan, restricted share
units or restricted share unit plans, or other benefit plans in force at the date hereof for directors, officers, employees, advisors
or consultants of the Company in their capacity as such, as such option or plan is amended or superseded from time to time in accordance
with the requirements of any applicable Principal Securities Exchange and Applicable Securities Laws, and such other benefit plans as
may be adopted by the Company in compliance with the requirements of any applicable Principal Securities Exchange and Applicable Securities
Laws,

 

and, for the avoidance of doubt, any such
issue shall be deemed not to be a Common Share Reorganization, Distribution or Capital Reorganization.

 

    - 9 -

     

    

 

		(d)	If a dispute at any time arises with respect to adjustments provided for in Section 2, the resolution
of such dispute will be conclusively determined, at the Company’s expense, by a firm of independent chartered accountants as may
be agreed by the Company and the Holder, each acting reasonably, and any such determination will be binding upon the Company and the Holder.
For the avoidance of doubt, the independent accountant referenced in this Section 3(d) may be, but is not required to be, the
same independent valuation expert contemplated by the definition of “Current Market Price”.

 

		(e)	If the Company sets a record date to determine the holders of the Common Shares for the purpose of effecting
a transaction described in Section 2 and thereafter and before effecting such transaction, legally abandons its plan to pay or deliver
such dividend, distribution, subscription or purchase rights, then no adjustment in the Exchange Basis by reason of the setting of such
record date shall be made.

 

		(f)	In the absence of a resolution of the directors fixing a record date for a Distribution, the Company will
be deemed to have fixed as the record date therefor the date on which the Distribution is affected.

 

		(g)	The Company will take any action which may be necessary or advisable in order for the Company to have
unissued and reserved in its authorized capital, and validly and legally issue as fully paid and non-assessable, all the shares or other
securities of the Company which the Holder is entitled to receive on the exercise of the Warrants following any adjustment set forth in
Section 2.

 

		(h)	Any adjustments to the Exchange Basis and the Exercise Price pursuant to this Warrant Certificate shall
be subject to the prior approval, if required, of the Principal Securities Exchange.

 

Section 4     Cashless
Exercise of Warrants.

 

Notwithstanding anything to the contrary
contained herein, and provided that the Warrants could otherwise be exercised in accordance with the terms hereof, the Holder may elect
to exercise the Warrants, in whole or in part, without payment of the aggregate Exercise Price due on such exercise (a “Cashless
Exercise”) in the manner set out in this Section 4. If the Holder elects a Cashless Exercise, the Holder shall provide
written notice of the election to the Company in the form of cashless exercise notice appended hereto as Schedule B or any other written
notice in a form reasonably satisfactory to the Company (a “Cashless Exercise Notice”). Upon actual receipt by the
Company of a Cashless Exercise Notice, a certificate or confirmation of book entry issuance (as directed by the Holder) for the appropriate
number of Common Shares will be delivered to the Person(s) in whose name(s) the Common Shares so subscribed for are to be issued
within two Business Days of receipt of the Cashless Exercise Notice (or if the share transfer books of the Company are properly closed,
within two Business Days of the opening of said share transfer books), such Person(s) shall become a holder in respect of such Common
Shares with effect from the date of such exercise, and, unless this Warrant Certificate has expired, a new Warrant Certificate representing
the unexercised balance of the Warrants, if any, or all of the Warrants evidenced by this Warrant Certificate having been exercised will
also be issued to the Holder within such time. Without limiting the rights of a Holder to receive Common Shares underlying this Warrant
on a “cashless exercise” and without limiting the liquidated damages provision contained herein, in no event will the Company
be required to net cash settle a Warrant exercise.

 

    - 10 -

     

    

 

		(a)	The number of Common Shares to be issued to the Holder upon a Cashless Exercise shall be determined as
follows:

 

 

 

	Where:	 	X =	the number of Common Shares to be issued to the Holder upon exercising the Warrants; provided, for the avoidance of doubt, that if the foregoing calculation results in a negative number, then no Common Shares shall be issuable via a Cashless Exercise;
	 	 	 	 
	 	 	Y =	the number of Warrants being exercised;
	 	 	 	 
	 	 	A =	the Current Market Price per Common Share as of the applicable exercise date; and
	 	 	 	 
	 	 	B =	the Exercise Price of the Warrants as of the applicable exercise date.

 

		(b)	If the number of Common Shares to be issued to the Holder exercising its Warrants on a cashless basis
in accordance with 0 above results in a fractional number, the Company will, in lieu of delivering the fractional Common Share, satisfy
the right to receive such fractional interest by payment to the Holder of an amount in cash equal (computed in the case of a fraction
of a cent to the next lower cent) to the value of the right to acquire such fractional interest on the basis of the Current Market Price
of the Common Shares on the date of exercise.

 

		(c)	If Holder elects the method of exercise set forth in this Section 4, the “exchange” of
the Warrants is intended to qualify as a recapitalization within the meaning of Section 368(a)(1)(E) of the U.S. Internal Revenue
Code of 1986, as amended, and, unless otherwise required by applicable Law, the parties hereto shall report consistently therewith for
all tax purposes.

 

    - 11 -

     

    

 

Section 5     Representations,
Warranties and Covenants.

 

The Company represents, warrants, covenants
and agrees that as of the date of this Warrant Certificate until the Time of Expiry:

 

		(a)	The Common Shares which may be issued upon the exercise of the Warrants represented by this Warrant Certificate
will, upon issuance and payment therefor of the amount at which such Common Shares may at the time be purchased pursuant to the provisions
hereof (including pursuant to a Cashless Exercise), be validly issued, fully paid and non-assessable and in each case, be free and clear
of any Liens (other than Liens granted by the Holder);

 

		(b)	The Company will reserve and keep available at all times a sufficient number of unissued Common Shares
out of its authorized capital to provide for the exercise in full, at any time, of the rights represented by this Warrant Certificate;

 

		(c)	The Company shall use its commercially reasonable efforts to maintain a listing of its Common Shares on
the NYSE American or other Principal Securities Exchange, provided that nothing contained in this clause (c) shall be construed to
limit (or to limit) the right of the Company to engage in a transaction that may result in it ceasing to be so listed;

 

		(d)	The Company has taken and will take all such actions as may be reasonably necessary and as are within
its power to ensure that all those Common Shares and Warrants issued or issuable pursuant to this Warrant Certificate may be so issued
without violation of Applicable Securities Law; and

 

		(e)	The Company will promptly advise the Holder of any defaults under this Warrant Certificate.

 

Section 6     Exercise
of Warrants.

 

		(1)	The Holder may exercise the right hereby conferred on the Holder to acquire Common Shares at any time
and from time to time prior to the Time of Expiry (subject to the provisions of this Section 6) by:

 

		(a)	duly completing and executing the subscription form (the “Subscription Form”) attached
as Schedule A to this Warrant Certificate (or any other written notice in a form satisfactory to the Company) and a Cashless Exercise
Notice, if applicable;

 

		(b)	surrendering this Warrant Certificate, together with, in the case of Warrants not being exercised on a
cashless basis in accordance with Section 4, the Holder’s certified check, bank draft, money order or wire transfer (or any
combination of the foregoing, in each case, in the discretion of the Holder) of immediately available funds in the full amount of the
total aggregate Exercise Price of each Warrant being exercised, together with the duly completed and executed Subscription Form (or
any other written notice in a form satisfactory to the Company) and Cashless Exercise Notice, if applicable, to the Company in accordance
with Section 12.

 

    - 12 -

     

    

 

		(2)	The Holder may exercise Warrants in respect of a number of Common Shares which is less than the total
number of Common Shares into which the Warrants evidenced by this Warrant Certificate may be exercised. In such a case, the Holder shall
be entitled to receive, at the Company’s expense, a new certificate in respect of the Warrants evidenced hereby that are not so
exercised. This Warrant Certificate shall be deemed to be surrendered only upon personal delivery thereof to, or if sent by mail or other
means of transmission, upon actual receipt thereof by, the Company in accordance with Section 12.

 

		(3)	One Warrant, together with the Exercise Price therefor, is required to purchase one Common Share, subject
to adjustment in accordance to the terms of this Warrant and to Cashless Exercise.

 

		(4)	The Warrants shall expire and all rights to purchase Common Shares hereunder shall cease and become null
and void at the Time of Expiry.

 

		(5)	Nothing herein contained or done pursuant hereto shall obligate the Holder to purchase or pay for, or
the Company to issue, any securities except those securities in respect of which the Holder shall have exercised its right to purchase
hereunder in the manner herein provided.

 

		(6)	Notwithstanding anything contained herein, including any adjustment provided for herein, the Company will
not be required to issue fractional Common Shares in satisfaction of its obligations hereunder. If any fractional interest in a Common
Share would be deliverable upon the exercise of a Warrant, the Company will, in lieu of delivering the fractional Common Share, satisfy
the right to receive such fractional interest by payment to the Holder of an amount in cash equal (computed in the case of a fraction
of a cent to the next lower cent) to the value of the right to acquire such fractional interest on the basis of the Current Market Price
of the Common Shares on the date of exercise.

 

		(7)	Notwithstanding anything herein contained, no Common Shares will be issued pursuant to the exercise of
any Warrant if the issuance of such Common Shares would, in the opinion of legal counsel to the Company, constitute a violation of the
Applicable Securities Laws of any applicable jurisdiction or the requirements of any Principal Securities Exchange, and without limiting
the generality of the foregoing, in the event that any of the Warrants are exercised prior to expiry of any hold period or other resale
restriction placed thereon by such Laws or requirements, the certificates evidencing the Common Shares thereby issued will bear such legend
as is required under Applicable Securities Laws and that, in the opinion of legal counsel to the Company, is necessary in order to avoid
a violation of any such Laws or requirements.

 

    - 13 -

     

    

 

Section 7     Reserved.

 

Section 8     Transfer
of Warrants.

 

		(1)	Other than as may be limited pursuant to Section 9, this Warrant Certificate and the Warrants represented
hereby may be transferred or assigned.

 

		(2)	This Warrant Certificate may only be transferred on the register of the Company by the Holder thereof
or its legal Representatives or attorney duly appointed by an instrument in writing in form and execution reasonably satisfactory to the
Company in accordance with applicable Laws. The Warrants and the Common Shares issuable hereunder are and may continue to be subject to
resale restrictions and hold periods, and the Holder should consult its legal advisor in respect of the same. Such transfer will be effected
upon surrender to the Company at the office of the Company in accordance with Section 12 hereof of this Warrant Certificate for cancellation
and the duly completed and executed transfer form (the “Transfer Form”) attached hereto as Schedule C, and upon compliance,
to the reasonable satisfaction of the Company, with:

 

		(a)	the conditions herein;

 

		(b)	such reasonable requirements as the Company may require; and

 

		(c)	all Applicable Securities Laws.

 

		(3)	After such transfer, the term “Holder” shall mean and include any transferee or assignee of
the current Holder or any subsequent Holder. Upon compliance with Section 8(2), the Company shall execute and deliver a new Warrant
Certificate or Warrant Certificates in the name of the assignee or assignees and in the denominations specified in such Transfer Form,
and shall issue to the assignor a new Warrant Certificate evidencing the portion of this Warrant, if any, not so assigned and this Warrant
Certificate shall promptly be cancelled.

 

		(4)	For each Warrant transferred, the Company shall charge to the Holder requesting such transfer a reasonable
sum for each new Warrant certificate issued, which sum shall solely cover the Company’s out-of-pocket expenses for such issuance,
and payment of such charges and reimbursement of the Company for any and all stamp taxes or governmental or other charges required to
be paid shall be made by the Holder requesting the transfer of this Warrant Certificate as a condition precedent thereto.

 

Section 9     Legend.

 

		(1)	Any certificate representing Common Shares issued in the United States or to or for the account or benefit
of a U.S. Person upon exercise of the Warrants will bear the following legends:

 

“THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) OR APPLICABLE
STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, OTHER THAN (A) PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OF THE UNITED STATES OR (B) PURSUANT
TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OF THE UNITED
STATES, AFTER THE HOLDER HAS FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY
SATISFACTORY TO THE COMPANY.

 

    - 14 -

     

    

 

Section 10     Not
a Shareholder.

 

Nothing in this Warrant Certificate
or in the holding of Warrants evidenced by this Warrant Certificate will be construed as conferring on the Holder any right or interest
whatsoever as a shareholder of the Company, including but not limited to, any right to vote at, to receive notice of, or to attend any
meeting of shareholders or any other proceeding of the Company or any right to receive any dividend or other distributions, prior to the
Holder’s exercise of Warrants in accordance with the terms hereof and the subscription for Common Shares in connection therewith.

 

Section 11     Amendment.

 

The terms of the Warrants
represented by this Warrant Certificate may be amended, and the observance of any term thereof may be waived, only by a written instrument
signed by the Company and the Holder of the Warrants.

 

Section 12     Notice.

 

		(1)	Any notice, direction or other instrument required or permitted to be given under this Warrant by or to
the Company or by or to the Holder shall be in writing and may be given by delivering by hand or by courier or by email to the following
addresses:

 

The Company:

 

Armata Pharmaceuticals, Inc.

4503 Glencoe Avenue

Marina del Rey, CA

Attn:     Chief
Executive Officer

Email:     info@armatapharma.com

 

    - 15 -

     

    

 

with a copy (which shall not constitute
notice) to:

 

Thompson Hine LLP

335 Madison Avenue

12th Floor

New York, New York 10017-4611

Attn: Faith L. Charles

Email: faith.charles@thompsonhine.com

 

The Holder:

 

c/o Innoviva

1350 Old Bayshore Highway Suite 400

Burlingame, CA 94010

Attention: Chief Executive Officer

Email: pavel.raifeld@inva.com

 

with a copy (which shall not constitute
notice) to:

 

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019

Attention: Jared Fertman

Email: jfertman@willkie.com

 

		(2)	Any notice, direction or instrument aforesaid shall:

 

		(i)	if personally delivered or delivered by courier, be deemed to have been given or made at the time of delivery
(with return receipt requested); and

 

		(ii)	if sent by email, be deemed to have been given or made upon confirmation of receipt.

 

The Company or the Holder may give written
notice of change of address in the same manner, in which event such notice or communication shall thereafter be given to it as above provided
at such changed address.

 

Section 13     Lost
Certificate.

 

Upon receipt of evidence satisfactory
to the Company of the loss, theft, destruction or mutilation of this Warrant Certificate and, if requested by the Company, upon delivery
of an indemnity satisfactory to the Company (or, in the case of mutilation, upon surrender of this Warrant Certificate), the Company will
issue to the Holder a replacement certificate of like denomination, tenor and date (containing the same terms and conditions as this Warrant
Certificate).

 

    - 16 -

     

    

 

Section 14     General.

 

		(1)	The Company may deem and treat the Holder of the Warrants as the absolute owner thereof for all purposes,
except where the Company should have actual notice or knowledge to the contrary or except where the Company is required to take notice
by statute or by Order of a court of competent jurisdiction. The Holder shall be entitled to the Warrants evidenced hereby, free from
all equities or rights of set off or counterclaim between the Company and the original or any intermediate holder of such Warrants. The
valid issue of Common Shares by the Company upon the exercise of Warrants by the Holder in accordance with the terms and conditions contained
herein shall discharge all responsibilities of the Company with respect to such Warrants and the Company shall not be bound to inquire
into the title of any such Holder except where the Company is required to take notice by statute or by Order of a court of competent jurisdiction.

 

		(2)	If any one or more of the provisions or parts thereof contained in this Warrant Certificate should be
or become invalid, illegal or unenforceable in any respect in any jurisdiction, the remaining provisions or parts thereof contained herein
shall be and shall be conclusively deemed to be, as to such jurisdiction, severable therefrom and:

 

		(a)	the validity, legality or enforceability of such remaining provisions or parts thereof shall not in any
way be affected or impaired by the severance of the provisions or parts thereof severed;

 

		(b)	the invalidity, illegality or unenforceability of any provision or part thereof contained in this Warrant
in any jurisdiction shall not affect or impair such provision or part thereof or any other provisions of this Warrant Certificate in any
other jurisdiction; and

 

		(c)	the Company and the Holder shall negotiate in good faith to modify this Warrant Certificate so as to effect
the original intent of the Company and the Holder as closely as possible in a mutually acceptable manner in order that the transactions
contemplated hereby be consummated and the economic benefits anticipated hereunder be as originally contemplated to the greatest extent
possible.

 

		(3)	Time shall be of the essence of this Warrant Certificate.

 

		(4)	In the event that any day on or before which any action is required to be taken hereunder is not a Business
Day, then such action shall be required to be taken on or before the requisite time on the next succeeding day that is a Business Day.
If the payment of any amount is deferred for any period, then such period shall be included for purposes of the computation of any interest
payable hereunder.

 

		(5)	This Warrant Certificate, the Securities Purchase Agreement dated as of [●], 2022 by and between
the Holder and the Company (the “Purchase Agreement”), and the other agreements, instruments and documents referenced
herein and therein, in each case as amended from time to time, constitute the sole and entire agreement of the parties to this Warrant
with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both
written and oral, with respect to such subject matter. In the event of any inconsistency between the provisions contained in this Warrant
and the Purchase Agreement, the provisions contained in this Warrant shall control.

 

    - 17 -

     

    

 

		(6)	This Warrant Certificate and all of its provisions shall enure to the benefit of the Holder, and its heirs,
executors, administrators, successors, legal Representatives and assigns and shall be binding upon the Company and its successors and
permitted assigns. The expression the “Holder” as used herein shall include the Holder’s assigns whether immediate or
derivative.

 

		(7)	This Warrant may be executed in counterparts, each of which shall be deemed an original, but all of which
together shall be deemed to be one and the same agreement. A signed copy of this Warrant delivered by facsimile, e-mail or other means
of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Warrant.

 

		(8)	The parties hereto acknowledge and agree that irreparable damage would occur in the event that any of
the provisions of this Warrant were not performed in accordance with their specific terms or were otherwise breached. It is accordingly
agreed that the parties hereto shall be entitled to an injunction or injunctions to prevent breaches or threatened breaches of this Warrant
and to enforce specifically the terms and provisions of this Warrant in any court of competent jurisdiction, in each case without proof
of damages or otherwise (and each party hereto hereby waives any requirement for the securing or posting of any bond in connection with
such remedy), this being in addition to any other remedy to which they are entitled at law or in equity. The parties hereto agree not
to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to law or inequitable for any reason, nor to assert
that a remedy of monetary damages would provide an adequate remedy.

 

		(9)	This Warrant shall be construed without regard to any presumption or rule requiring construction
or interpretation against the party drafting an instrument or causing any instrument to be drafted.

 

		(10)	This Warrant shall be governed by, and construed in accordance with, the Laws of the State of Delaware
but the reference to such Laws shall not, by conflict of laws rules or otherwise, require the application of the Law of any jurisdiction.
The Company and the Holder each hereby irrevocably agree to the exclusive jurisdiction of the Chancery Court of the State of Delaware
(or, if the Court of Chancery of the State of Delaware declines to accept jurisdiction, any state or federal court within the State of
Delaware), for the purposes of any action or legal proceeding arising out of this Warrant and the rights and obligations arising hereunder,
and irrevocably and unconditionally waives any objection to the laying of venue of any such action or legal proceeding in any such court,
and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action or legal proceeding
has been brought in an inconvenient forum. Each party hereto agrees that service of any process, summons, notice or document by registered
mail to such party’s respective address set forth in Section 11 shall be effective service of process for any such action or
legal proceeding.

 

    - 18 -

     

    

 

		(11)	Each party hereto hereby waives, to the fullest extent permitted by applicable Law, any right it may have
to a trial by jury in respect of any action or legal proceeding directly or indirectly arising out of, under or in connection with this
Warrant.

 

[Remainder of page intentionally left blank.
Signature page follows.]

 

    - 19 -

     

    

 

IN
WITNESS WHEREOF the Company has caused this Warrant Certificate to be signed by its duly authorized officer and this Warrant
Certificate to be dated [●], 2022.

 

	ARMATA PHARMACUETICALS, INC.	 
	 	 
	 	 
	Per:	 	 
	 	Name:	 
	 	Title:	 

 

    - 20 -

     

    

 

Schedule A

 

SHARE
PURCHASE WARRANT

 

SUBSCRIPTION FORM

 

(To be signed only upon exercise of such Warrant)

 

Armata Pharmaceuticals, Inc.

 

The
undersigned hereby exercises the right to purchase and hereby subscribes for _____________ common shares of Armata Pharmaceuticals, Inc.
(the “Company”) referred to in the Warrant Certificate dated [●], 2022 (the “Warrant Certificate”)
attached hereto according to the conditions thereof, and herewith makes payment of the purchase price in full for the common shares. Capitalized
terms used herein but not otherwise defined shall have the meanings ascribed to them in the Warrant Certificate.

 

If any Warrants represented
by the Warrant Certificate are not being exercised, a new Warrant Certificate will be issued by the Company and delivered to the undersigned
with the common share certificates.

 

Please issue the common shares
in the following manner (Please check the ONE box applicable):

 

	 ̈	Issue a certificate for the common shares being purchased in the name of the undersigned.
	 	 
	 ̈	Effect book entry issuance for the common shares being purchased in the name of the undersigned.

 

	NAME:	 	 
	 	(please print)	 
	NUMBER OF	 	 
	COMMON SHARES:	 	 
	ADDRESS:	 	 
	 	 	 
	 	 	 

 

DATED
this_________________ day of ________________, 20__.

 

	 	 
	 	(Signature)

 

     - 21 -

     

    

 

Schedule B

 

CASHLESS
EXERCISE NOTICE

 

Armata Pharmaceuticals, Inc.

 

The undersigned hereby exercises
the right to purchase and hereby subscribes for __________ common shares of Armata Pharmaceuticals, Inc. referred to in the Warrant
Certificate dated [●], 2022 (the “Warrant Certificate”) attached hereto according to the conditions thereof,
on a cashless basis pursuant to Section 4 of the Warrant Certificate. Capitalized terms used herein but not otherwise defined shall
have the meanings ascribed to them in the Warrant Certificate.

 

The number of Common Shares
to be issued in accordance with the accompanying Subscription Form shall be calculated based on the formula set out in Section 4(a) of
the Warrant Certificate.

 

DATED
this _____ day of _______________, 20____.

 

	 	 
	 	(Signature)

 

     - 22 -

     

    

 

Schedule C

 

TRANSFER FORM

 

FOR
VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto ___________________________________________________(include
name and address of the transferee) _____________     Warrants exercisable
for common shares of Armata Pharmaceuticals, Inc. (the “Company”) issued in the name of the undersigned
on the register of the Company maintained therefore, and hereby irrevocably appoints _________________________________ the attorney of
the undersigned to transfer the said securities on the books maintained by the Company with full power of substitution.

 

DATED
this__________ day of ________________________, 20__.

 

	 	 	 
	 	Signature of Transferor	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	Address of Transferor	 

 

Notes:

 

		1.	The signature to this transfer must correspond with the name written upon the face of this Warrant
Certificate in every particular without any changes whatsoever.

 

     - 23 -Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (together with all Exhibits and Schedules hereto, as each may be amended, restated, amended and restated,
supplemented or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), dated
as of February 9, 2022, is made by and between (i) Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”),
and (ii) Innoviva Strategic Opportunities LLC, a Delaware limited liability company (the “Purchaser”). The Company
and the Purchaser are referred to herein individually as a “Party”, and, collectively as the “Parties.”

 

RECITALS

 

WHEREAS, subject to the terms
and conditions contained in this Agreement, at the Closings (as defined below), the Company intends to issue and sell to the Purchaser
(a) 9,000,000 shares of fully paid and non-assessable Common Stock (the “Purchased Common Stock”) and (b) Warrants
to purchase 4,500,000 shares of Common Stock (as may be adjusted pursuant to Section 2.1(a)) (the “Purchased Warrants”),
and the Purchaser desires to purchase such Common Stock and Warrants from the Company

 

WHEREAS, each share of Purchased
Common Stock and each Purchased Warrant will be issued and sold to the Purchaser as a unit at the First Closing and the Second Closing,
as applicable, for a per unit price of $5.00 (the “Per Unit Purchase Price”) payable in accordance with the terms hereof;
and

 

WHEREAS, the Board has unanimously
determined that this Agreement and the transactions contemplated hereby are advisable, fair and in the best interests of the Company and
its stockholders.

 

NOW, THEREFORE, in consideration
of the mutual promises, agreements, representations, warranties and covenants contained herein, the Company (on behalf of itself and each
of its direct and indirect Subsidiaries) and the Purchaser agree as follows:

 

Article I

 

DEFINITIONS

 

Section 1.1     Definitions.
Except as otherwise expressly provided in this Agreement, whenever used in this Agreement (including any Exhibits and Schedules hereto),
the following terms shall have the respective meanings specified therefor below:

 

“2020 Warrants”
means the warrants purchased by the Purchaser pursuant to the 2020 Purchase Agreement.

 

“2020 Purchase Agreement”
means that certain Securities Purchase Agreement, dated as of January 27, 2020, by and between the Company and Innoviva, Inc.

 

     

     

    

 

“2021 Warrants”
means the warrants purchased by the Purchaser pursuant to that certain Securities Purchase Agreement, dated as of January 26, 2021,
by and between the Company and the Purchaser.

 

“2021 Purchase Agreements”1
means (a) that certain Securities Purchase Agreement, dated as of January 26, 2021, by and between the Company and the Purchaser,
and (b) that certain Securities Purchase Agreement, dated as of October 28, 2021, by and between the Company, Cystic Fibrosis
Foundation, and the Purchaser.

 

“Acquisition Proposal”
has the meaning set forth in Section 5.2.

 

“Action”
means, any action, suit, claim, arbitration, mediation, litigation, hearing, or other proceeding by or before any court, tribunal or arbitrator
or any Governmental Entity.

 

“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly, Controls or is Controlled by or is under common
Control with such Person; provided, however, that neither Purchaser nor any of its Affiliates shall be deemed to be an Affiliate
of the Company or any of its direct and indirect Subsidiaries for purposes of this Agreement. “Affiliated” has a correlative
meaning.

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Board” means
the Board of Directors of the Company.

 

“Business Day”
means any day that is not a Saturday, Sunday or other day on which commercial banks are required or permitted to be closed in the State
of California.

 

“Bylaws”
means the Company’s bylaws, as amended through the date hereof.

 

“Capital Stock”
means (a) any shares, interests, participations or other equivalents (however designated) of capital stock of a corporation; (b) any
ownership interests in a Person other than a corporation, including membership interests, partnership interests, joint venture interests
and beneficial interests; and (c) any warrants, options, convertible or exchangeable securities, subscriptions, rights (including
any preemptive or similar rights), calls or other rights to purchase or acquire any of the foregoing.

 

“Certificate of Incorporation”
means the certificate of incorporation of the Company, as amended through the date hereof.

 

“Closings”
means, collectively, the First Closing and the Second Closing.

 

“Common Stock”
means the common stock, par value $0.01 per share, of the Company, and any Capital Stock into which such Common Stock shall have been
converted, exchanged or reclassified following the date hereof.

 

 

1 NTD: Ensure references to Purchaser in this definition
are correct if the Purchaser entity changes.

 

     2

     

    

 

“Company”
has the meaning set forth in the Preamble.

 

“Company Organizational
Documents” mean the Certificate of Incorporation and the Bylaws.

 

“Company’s Knowledge,”
 “Knowledge of the Company” or “Knowledge” means the actual knowledge of Brian Varnum, Todd R. Patrick
and Steve R. Martin.

 

“Contract”
means any agreement, contract or instrument, including any loan, note, bond, mortgage, indenture, guarantee, deed of trust, license, franchise,
commitment, lease, franchise agreement, letter of intent, memorandum of understanding or other obligation, and any amendments thereto,
whether written or oral.

 

“Control”
means, with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of such Person, whether through the ownership of voting securities or by contract or agency or otherwise. “Controlled”
has a correlative meaning.

 

“Definitive Documents”
means this Agreement, the Registration Rights Agreement, the Warrant Certificate, the Voting Agreement and each of the other agreements
and instruments entered into and delivered by the Parties hereto in connection with the transactions contemplated hereby.

 

“Environmental Laws”
means all applicable federal, state, local or foreign Laws relating to pollution or protection of human health or the environment (including
ambient air, surface water, groundwater, land surface or subsurface strata), including Laws relating to emissions, discharges, releases
or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous
Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage,
disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, demands or demand letters, licenses, notices
or notice letters, Orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

“ERISA” means
the Employee Retirement Income Security Act of 1974, as amended from time to time, and the regulations thereunder.

 

“ERISA Affiliate”
means any trade or business (whether or not incorporated) that together with the Company or any of its Subsidiaries is treated as a single
employer within the meaning of Section 414 of the Code or Section 4001 of ERISA.

 

“ERISA Event”
means (1) a Reportable Event with respect to a Pension Plan; (2) a withdrawal by the Company, any of its Subsidiaries or any
of their respective ERISA Affiliates from a Pension Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial
employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as a termination under Section 4062(e) of
ERISA; (3) a complete or partial withdrawal by the Company, any of its Subsidiaries or any of their respective ERISA Affiliates from
a Multiemployer Plan, written notification of any member of the Consolidated Group or any of their respective ERISA Affiliates concerning
the imposition of Withdrawal Liability or written notification that a Multiemployer Plan is in reorganization within the meaning of Title
IV of ERISA or that a Multiemployer Plan has been determined to be in “endangered” or critical status (within the meaning
of Section 432 of the Code or Section 305 of ERISA); (4) the filing under Section 4041(c) of ERISA of a notice
of intent to terminate a Pension Plan, the treatment of a Pension Plan or Multiemployer Plan amendment as a termination under Sections
4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Pension Plan or Multiemployer Plan; (5) the
imposition of any liability under Title IV of ERISA, other than for the payment of plan contributions or PBGC premiums due but not delinquent
under Section 4007 of ERISA, upon the Company, any of its Subsidiaries or any of their respective ERISA Affiliates, (6) the
failure to satisfy the minimum funding standards (within the meaning of Section 412 of the Code or Section 302 of ERISA) with
respect to any Pension Plan, (7) the application for a minimum funding waiver under Section 302(c) of ERISA with respect
to a Pension Plan, (8) the imposition of a Lien under Section 303(k) of ERISA with respect to any Pension Plan, (9) a
determination that any Pension Plan is in “at risk” status (within the meaning of Section 303 of ERISA), or (10) the
Company, any of its Subsidiaries or any of their respective ERISA Affiliates has engaged in a transaction that is subject to Sections
4069 or 4212(c) of ERISA.

 

     3

     

    

 

“Expense Reimbursement”
means the reimbursement obligation contemplated by Section 5.9.

 

“First Closing”
has the meaning set forth in Section 2.2(a).

 

“First Closing Date”
has the meaning set forth in Section 2.2(a).

 

“First Common Stock”
means the maximum number of shares of Common Stock issuable at the First Closing to Purchaser in compliance with any and all Laws and
without the requirement for the prior receipt of the Stockholder Approval under the listing requirements of the NYSE American, assuming
that Warrants to purchase an equal number of shares of Common Stock are also issued to Purchaser at the First Closing.

 

“First Purchase Price”
means an amount in cash equal to the product of (i) the number of shares of First Common Stock multiplied by (ii) the
Per Unit Purchase Price.

 

“First Warrants”
means Warrants to purchase a number of shares of Common Stock equal to one half of the number of shares of First Common Stock.

 

“Fundamental Representations”
has the meaning set forth in Section 9.13.

 

“GAAP” means
United States generally accepted accounting principles, consistently applied, as in effect from time to time.

 

“Governmental Entity”
means any applicable nation, state, county, city, town, village, district or other political jurisdiction of any nature, federal, state,
local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental
agency, branch, department, official, or entity and any court or other tribunal), stock exchange, multi-national organization or body,
or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or Taxing authority
or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a government
or a public international organization or any of the foregoing.

 

     4

     

    

 

“Indebtedness”
means (a) any indebtedness or other obligation for borrowed money, whether current, short-term or long-term and whether secured or
unsecured; (b) any indebtedness evidenced by any note, bond, debenture or other security or similar instrument; (c) any liabilities
with respect to interest rate or currency swaps, collars, caps and similar hedging obligations; (d) any liabilities in respect of
any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which liabilities
are required to be classified and accounted for under GAAP as capital leases; (e) any liabilities under any performance bond or letter
of credit or any bank overdrafts and similar charges; (f) any accrued interest, premiums, penalties and other obligations relating
to the foregoing items in clauses (a) through (e); and (g) any indebtedness referred to in clauses (a) through (f) above
of any Person that is either guaranteed (including under any “keep well” or similar arrangement) by, or secured (including
under any letter of credit, banker’s acceptance or similar credit transaction) by any Lien upon any property or asset owned by,
the Company or any of its Subsidiaries.

 

“Insolvent”
means, (i) with respect to the Company and its Subsidiaries, on a consolidated basis, (A) the present fair saleable value of
the Company’s and its Subsidiaries’ assets is less than the amount required to pay the Company’s and its Subsidiaries’
total Indebtedness, (B) the Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent
or otherwise, as such debts and liabilities become absolute and matured or (C) the Company and its Subsidiaries intend to incur or
believe that they will incur debts that would be beyond their ability to pay as such debts mature; and (ii) with respect to the Company
and each Subsidiary, individually, (A) the present fair saleable value of the Company’s or such Subsidiary’s (as the
case may be) assets is less than the amount required to pay its respective total Indebtedness, (B) the Company or such Subsidiary
(as the case may be) is unable to pay its respective debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities
become absolute and matured or (C) the Company or such Subsidiary (as the case may be) intends to incur or believes that it will
incur debts that would be beyond its respective ability to pay as such debts mature.

 

“Law” means
any law, statute, code, ordinance, regulation or rule of any Governmental Entity.

 

“Lien” means
any lien, adverse claim, charge, option, right of first refusal, preemptive right, servitude, security interest, mortgage, pledge, deed
of trust, easement, encumbrance, restriction on transfer, Taxes, conditional sale or other title retention agreement, defect in title
or other restrictions of any kind; provided that restrictions on transfer arising under applicable securities Laws shall not be
Liens.

 

“Material Adverse Effect”
means any effect, change, event, development, condition or occurrence that, individually or together with one or more effects, changes,
events, developments, conditions or occurrences, has had or would be reasonably expected to have or result in a material adverse effect
or material adverse change on the business, assets, liabilities, properties, financial condition or operating results of the Company and
its Subsidiaries, taken as a whole, or to the ability of the Company to consummate timely the transactions contemplated by this Agreement.

 

     5

     

    

 

“Material Contract”
means any Contract that would be required to be filed by the Company as a “material contract” pursuant to Item 601(b)(10) of
Regulation S-K under the Securities Act.

 

“Multiemployer Plan”
means any multiemployer plan as defined in Section 4001(a)(3) of ERISA and subject to Title IV of ERISA, to which any member
of the Consolidated Group or any of their respective ERISA Affiliates makes or is obligated to make contributions, or, during the preceding
five (5) plan years, has made or has been obligated to make contributions.

 

“NYSE American”
means the NYSE American stock exchange maintained by the New York Stock Exchange (NYSE).

 

“Order” means
any judgment, order, award, injunction, writ, permit, license, settlement or decree issued, promulgated, made, rendered or entered into
by or with any Governmental Entity or arbitrator of applicable jurisdiction (in each case, whether temporary, preliminary or permanent).

 

“Party” or
 “Parties” has the meaning set forth in the Preamble.

 

“PBGC” means
the Pension Benefit Guaranty Corporation.

 

“Pension Plan”
means any “employee pension benefit plan” (as such term is defined in Section 3(2) of ERISA), other than a Multiemployer
Plan, that is subject to Title IV of ERISA and is sponsored or maintained by the Company, any of its Subsidiaries or any of their respective
ERISA Affiliates or to which the Company, any of its Subsidiaries or any of their respective ERISA Affiliates contributes or has an obligation
to contribute or has made or has had an obligation to make contributions at any time in the preceding five plan years.

 

“Person”
means an individual, firm, corporation (including any non-profit corporation), partnership, limited liability company, joint venture,
association, trust, Governmental Entity or other entity or organization.

 

“Plan” means
any material “employee benefit plan” (as such term is defined in Section 3(3) of ERISA) established by the Company
or any of its Subsidiaries, or, with respect to any such plan that is subject to Section 412 of the Code or Title IV of ERISA, any
of their respective ERISA Affiliates.

 

“Registration Rights
Agreement” has the meaning set forth in Section 5.5.

 

“Related Party”
means, with respect to any Person, (a) any former, current or future director, officer, agent, Affiliate, employee, general or limited
partner, member, manager or stockholder of such Person and (b) any former, current or future director, officer, agent, Affiliate,
employee, general or limited partner, member, manager or stockholder of any of the foregoing.

 

“Reportable Event”
means, with respect to any Pension Plan, any of the events set forth in Section 4043(c) of ERISA or the regulations issued thereunder,
other than events for which the thirty (30) day notice period has been waived.

 

     6

     

    

 

“Representatives”
means, with respect to any Person, such Person’s directors, officers, members, partners, managers, employees, agents, investment
bankers, attorneys, accountants, advisors and other representatives.

 

“Required Minimum”
means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable in the future pursuant
to this Agreement, the 2020 Purchase Agreement, or the 2021 Purchase Agreements including the shares of Common Stock issuable upon exercise
in full of all 2020 Warrants, 2021 Warrants, and the Purchased Warrants.

 

“Sanctioned Country”
means any country or region that is subject or target of a comprehensive trade embargo under Sanctions.

 

“Sanctioned Person”
means any individual or entity that is the subject or target of Sanctions, including (i) any individual or entity listed on any Sanctions-related
restricted party list, including the U.S. Department of Treasury, Office of Foreign Asset Control’s (“OFAC”)
Specially Designated Nationals and Blocked Persons List and the EU Consolidated List, (ii) any entity that is owned, directly or
indirectly, or otherwise controlled by a Person or Persons described in clause (i) above, (iii) any national, resident, government,
agency, or instrumentality of a Sanctioned Country or (iv) any individual or entity otherwise the subject or target of Sanctions.

 

“Sanctions”
means all applicable Laws relating to economic, financial or trade sanctions, including any such Laws administered or enforced by the
U.S. government (including by OFAC or the U.S. Department of State), the United Nations Security Council, the European Union, the United
Kingdom (include by Her Majesty’s Treasury) or any other relevant Governmental Entity that administers or enforces economic, financial
or trade sanctions.

 

“SEC” means
the United States Securities and Exchange Commission.

 

“SEC Documents”
has the meaning set forth in Section 3.8(a).

 

“Second Closing”
has the meaning set forth in Section 2.3.

 

“Second Closing Date”
has the meaning set forth in Section 2.3.

 

“Second Common Stock”
means an amount equal to (i) the aggregate number of shares of Purchased Common Stock, minus (ii) the number of shares
of First Common Stock.

 

“Second Purchase Price”
means an amount in cash equal to the product of (i) the number of shares of Second Common Stock multiplied by (ii) the
Per Unit Purchase Price.

 

“Second Warrants”
means Warrants to purchase a number of shares of Common Stock equal to one half of the number of shares of Second Common Stock.

 

“Securities”
means the Purchased Common Stock and the Purchased Warrants (including the shares of Common Stock issuable upon exercise of the Purchased
Warrants), in each case, that will be delivered to Purchaser pursuant to this Agreement.

 

     7

     

    

 

“Securities Act”
means the Securities Act of 1933, and the rules and regulations promulgated thereunder.

 

“Stockholder Approval”
means such approval as may be required by the applicable rules and regulations of NYSE American (or any successor entity) from the
stockholders of the Company with respect to the transactions contemplated by this Agreement and the other Definitive Documents.

 

“Stockholders”
means, collectively, Purchaser and Innoviva, Inc.

 

“Subsidiary”
means, with respect to any Person, any corporation, partnership, joint venture or other legal entity as to which such Person (either alone
or through or together with any other subsidiary), (a) owns, directly or indirectly, more than fifty percent (50%) of the stock or
other equity interests, (b) has the power to elect a majority of the board of directors or similar governing body, or (c) has
the power to direct the business and policies.

 

“Tax Contest”
means any audit, suit, conference, action, assessment, investigation, claim, administrative or judicial proceeding, or other similar interaction
with a Governmental Entity with respect to any Tax.

 

“Tax Returns”
means any and all reports, returns, declarations, claims for refund, elections, disclosures, estimates, information reports or returns
or statements supplied or required to be supplied to a Governmental Entity in connection with Taxes, including any schedule or attachment
thereto or amendment thereof.

 

“Taxes” means
(i) all taxes, assessments, duties, levies or other similar governmental charges paid or payable to a Governmental Entity, including
all federal, state, local, foreign and other income, franchise, profits, gross receipts, capital gains, capital stock, transfer, property,
sales, use, value-added, occupation, excise, severance, windfall profits, stamp, payroll, social security, withholding and other taxes,
assessments, duties, levies (whether payable directly or by withholding and whether or not requiring the filing of a return), all estimated
taxes, deficiency assessments, additions to tax, penalties and interest thereon, (ii) any liability for such amounts described in
clause (i) as a result of being a member of a combined, consolidated, unitary, or affiliated group and (iii) any and all
liability for the payment of any amounts described above in clauses (i) and (ii) as a result of any express or implied obligation
to indemnify any other person, or any successor or transferee liability. “Taxing” and “Taxation” each have a correlative
meaning.

 

“Voting Agreement”
means the voting agreement to be entered into by the Purchaser and the Company, in substantially the form set forth on Exhibit A
hereto.

 

“Warrant Certificate”
means the certificate in substantially the form attached hereto as Exhibit B.

 

“Warrants”
means warrants to purchase shares of Common Stock, at an exercise price of $5.00 per share, represented by and on the terms set forth
herein and in the Warrant Certificate.

 

     8

     

    

 

“Withdrawal Liability”
means the liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such term
is defined in Part I of Subtitle E of Title IV of ERISA.

 

Section 1.2     Construction.
In this Agreement, unless the context otherwise requires:

 

(a)            references
to Articles, Sections, Exhibits and Schedules are references to the articles and sections or subsections of, and the exhibits and
schedules attached to, this Agreement;

 

(b)            references
in this Agreement to “writing” or comparable expressions include a reference to a written document transmitted by means of
electronic mail in portable document format (pdf), facsimile transmission or comparable means of communication;

 

(c)            words
expressed in the singular number shall include the plural and vice versa; words expressed in the masculine shall include the feminine
and neuter gender and vice versa;

 

(d)            the
words “hereof,” “herein,” “hereto” and “hereunder,” and words of similar import, when
used in this Agreement, shall refer to this Agreement as a whole, including all Exhibits and Schedules attached to this Agreement, and
not to any provision of this Agreement;

 

(e)            the
term “this Agreement” shall be construed as a reference to this Agreement as the same may have been, or may from time to time
be, amended, modified, varied, novated or supplemented;

 

(f)            “include,”
 “includes” and “including” are deemed to be followed by “without limitation” whether or not they are
in fact followed by such words;

 

(g)            references
to “day” or “days” are to calendar days;

 

(h)            if
the last day for the giving of any notice or the performance of any act required or permitted under this Agreement is a day that is not
a Business Day, then the time for the giving of such notice or the performance of such action shall be extended to the next succeeding
Business Day;

 

(i)            references
to “the date hereof” or “the date of the Agreement” means the date of this Agreement;

 

(j)            references
to “ordinary course of business” means the ordinary and usual course of normal day-to-day operations of the Company, consistent
with past practices

 

(k)            the
word “or” is disjunctive but not necessarily exclusive;

 

(l)            unless
otherwise specified, references to any Law means such Law as amended from time to time and includes any successor Law thereto and any
rules or regulations promulgated thereunder in effect from time to time; and

 

     9

     

    

 

(m)            references
to “dollars” or “$” refer to currency of the United States of America, unless otherwise expressly provided.

 

Article II

 

PURCHASE AND SALE

 

Section 2.1     The
Purchase and Sale.

 

(a)            On
the terms and subject to the conditions set forth herein, at the First Closing, the Purchaser hereby agrees to purchase (or cause certain
of its Subsidiaries to purchase), and the Company shall sell to Purchaser (or such Subsidiaries) in exchange for the First Purchase Price,
(i) the First Common Stock, free and clear of all Liens and (ii) the First Warrants, free and clear of all Liens.

 

(b)            On
the terms and subject to the conditions set forth herein, at the Second Closing, the Purchaser hereby agrees to purchase (or cause certain
of its Subsidiaries to purchase), and the Company shall sell to Purchaser (or such Subsidiaries) in exchange for the Second Purchase Price,
(i) the Second Common Stock, free and clear of all Liens and (ii) the Second Warrants, free and clear of all Liens; provided,
that, if during the period from the date hereof until and including the Second Closing, the Company issues to any Person any shares of
Common Stock or Capital Stock or similar securities convertible into, exchangeable for or having the right to subscribe for shares of
Common Stock at a price per share less than the Per Unit Purchase Price (other than shares of Common Stock issued upon the exercise of
options, warrants or similar securities outstanding as of the date hereof), the number of Warrants issued to the Purchaser at the Second
Closing will be proportionally and ratably increased such that the Warrants issued to Purchaser will not be affected by any such dilution.

 

(c)            The
Parties agree that the Common Stock and Warrants to be purchased by Purchaser hereunder shall be issued in reliance upon the exemption
from registration set forth in Section 4(a)(2) of the Securities Act.

 

Section 2.2     First
Closing.

 

(a)            The
closing of the purchase of the First Common Stock and First Warrants (the “First Closing”) shall take place on the
date hereof (the “First Closing Date”) remotely via the electronic exchange of documents and signatures. At the First
Closing, the Company shall issue the First Common Stock and First Warrants to the Purchaser free and clear of all Liens against payment
by the Purchaser of the First Purchase Price.

 

(b)            At
the First Closing, the Company shall:

 

(i)            deliver
or cause to be delivered to the Purchaser:

 

(A)            a
certificate of good standing of the Company as of a date no earlier than two (2) Business Days prior to the First Closing Date;

 

     10

     

    

 

(B)            counterparts
to Warrant Certificates representing the full number of First Warrants;

 

(C)            copies
of the resolutions or written consents duly adopted by the Board and certified by the Company’s secretary authorizing the execution,
delivery and performance of this Agreement and the transactions contemplated hereby (including authorization of the transactions contemplated
hereunder pursuant to Section 23B.19.040 of Washington Business Corporation Act); and

 

(D)            a
counterpart to the Registration Rights Agreement, duly executed by the Company; and

 

(E)            a
counterpart to the Voting Agreement, duly executed by the Company;

 

(ii)            deliver
or cause to be delivered any other customary documents or certificates reasonably requested by Purchaser which are reasonably necessary
to give effect to the Closing; and

 

(iii)            pay,
or cause to be paid to Purchaser (which may be set off against the First Purchase Price), any portion of the Expense Reimbursement then
accrued and unpaid.

 

(c)            At
the First Closing, Purchaser shall deliver or cause to be delivered to the Company a counterpart to the Voting Agreement, duly executed
by the Stockholders.

 

Section 2.3     Second
Closing.

 

(a)            The
closing of the purchase of the Second Common Stock and Second Warrants (the “Second Closing”) shall take place remotely
via the electronic exchange of documents and signatures, or at such other time and place as the Parties may agree in writing, on the first
(1st) Business Day after satisfaction or waiver of the conditions set forth in Section 6.1 (other than those conditions that
by their terms are to be satisfied at the Second Closing, but subject to the satisfaction or waiver of those conditions). The date on
which the Second Closing actually occurs shall be referred to herein as the “Second Closing Date.” At the Second Closing,
the Company shall issue the Second Common Stock and Second Warrants to the Purchaser free and clear of all Liens against payment by the
Purchaser of the Second Purchase Price.

 

(b)            At
the Second Closing, the Company shall:

 

(i)            deliver
or cause to be delivered to the Purchaser:

 

(A)            a
certificate of good standing of the Company as of a date no earlier than two (2) Business Days prior to the Second Closing Date;

 

(B)            the
certificate contemplated by Section 6.1(f); and

 

     11

     

    

 

(C)            counterparts
to Warrant Certificates representing the full number of Second Warrants (as may be adjusted pursuant to Section 2.1(b));

 

(ii)            pay,
or cause to be paid to Purchaser (which may be set off against the Second Purchase Price), any portion of the Expense Reimbursement then
accrued and unpaid; and

 

(iii)            deliver
or cause to be delivered any other customary documents or certificates reasonably requested by Purchaser which are reasonably necessary
to give effect to the Closing.

 

Article III

 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

Except as set forth in the
SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC’s Electronic Data Gathering Analysis
and Retrieval system (but excluding any forward-looking disclosures set forth in any “risk factors” section, any disclosures
in any “forward-looking statements” section and any other disclosures included therein to the extent they are predictive or
forward-looking in nature), the Company hereby represents and warrants to the Purchaser as of the date hereof, and as of the Second Closing,
as follows:

 

Section 3.1     Organization
and Qualification. The Company and each of its Subsidiaries are entities duly organized, validly existing and in good standing under
the Laws of the jurisdiction in which they are formed, and each has the requisite power and authority to own its properties and to carry
on its business as now being conducted and as presently proposed to be conducted. The Company and each of its Subsidiaries is duly qualified
as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of
the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good
standing would not, individually or in the aggregate, have a Material Adverse Effect. Other than the Persons set forth on Exhibit 21.1
to the Company’s Annual Report on Form 10-K, filed with the SEC on March 18, 2021, the Company has no Subsidiaries and
does not own Capital Stock in any other Person.

 

Section 3.2     Authorization;
Enforcement; Validity. Subject to the Stockholder Approval, the Company has the requisite power and authority to enter into and perform
its obligations under the Agreement and the other Definitive Documents, to consummate the transactions contemplated hereby and thereby
and to issue the Securities in accordance with the terms hereof and thereof. The execution and delivery of the Agreement and the other
Definitive Documents by the Company, and the consummation by the Company of the transactions contemplated hereby and thereby (including
the issuance of the Securities and the reservation for issuance and issuance of Common Stock issuable upon the exercise of the Warrants
in accordance with, and pursuant to, the Warrant Certificate) have been duly authorized by the Company, and such authorization has not
been, and as of the Closing will not have been, subsequently rescinded or modified in any way, and, no further filing, consent or authorization
is or will be required to be made by or on behalf of the Company, its Subsidiaries and their respective boards of directors, stockholders
or other governing bodies in connection with the transactions contemplated by the Definitive Documents. The Agreement has been, and the
other Definitive Documents to which the Company is a party will be, prior to the First Closing or Second Closing, as applicable, duly
executed and delivered by the Company, and each constitutes the legal, valid and binding obligations of the Company, enforceable against
the Company in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement
of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution may be limited by applicable
federal or state securities Law (the “General Enforceability Exceptions”).

 

     12

     

    

 

Section 3.3     Issuance
of Securities. The issuance of the Securities is duly authorized, and upon issuance in accordance with the terms of the Definitive Documents
will be validly issued, fully paid and non-assessable (to the extent such concepts are applicable) and free and clear of all Liens. The
issuances of the Securities in connection with the transactions contemplated by the Definitive Documents are in compliance, in all respects,
with all applicable Laws, and the Securities are not subject to, and will not be issued in violation of, any purchase options, call options,
rights of first refusal, preemptive rights, subscription rights or any similar rights under applicable Law, the Company Organizational
Documents or any Contract to which the Company or any of its Subsidiaries is a party or by which it is bound. Subject to the accuracy
of the representations and warranties of the Purchaser set forth in Article IV, the offer and issuance by the Company of the Securities
is exempt from registration under the Securities Act. As of the First Closing, the Company will have reserved from its duly authorized
Capital Stock the maximum number of shares of Common Stock issuable upon the exercise of the Purchased Warrants. Upon the issuance of
Common Stock following an exercise of the Purchased Warrants in accordance with the Warrant Certificate, such Common Stock, when issued,
will be validly issued, fully paid and non-assessable and free and clear of all Liens, with the holders thereof being entitled to all
rights accorded to a holder of Common Stock.

 

Section 3.4     No
Conflicts. The execution, delivery and performance of this Agreement and the other Definitive Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including the issuance of the Securities and the reservation for
issuance and issuance of Common Stock issuable upon the exercise of the Purchased Warrants in accordance with the Warrant Certificate)
will not (i) result in a violation of the Certificate of Incorporation, Bylaws, certificate of formation, memorandum of association,
articles of association, bylaws or other organizational documents of the Company or any of its Subsidiaries (collectively, the “Group
Companies Organizational Documents”), (ii)  conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any Contract that would be required to be filed by the Company as a “material contract” pursuant to Item
601(b)(10) of Regulation S-K under the Securities Act or other agreement, indenture or instrument to which the Company or any of
its Subsidiaries is a party, other than (a) the acceleration of vesting of restricted stock awards set forth in the SEC Documents
and (b) the deemed exercise of warrants to purchase Common Stock set forth in the SEC Documents, or (iii) result in a material
violation of any Law (including, for the avoidance of doubt, foreign, federal and state securities Laws and the rules and regulations
of the NYSE American) or Order that would be material to the business of the Company and its Subsidiaries taken as a whole.

 

     13

     

    

 

Section 3.5     Consents.
Other than the Stockholder Approval, neither the Company nor any Subsidiary is required to obtain any consent from, authorization or
order of, or make any filing or registration with any Governmental Entity or any regulatory or self-regulatory agency or any other Person
in order for it to execute, deliver or perform any of its respective obligations under or contemplated by this Agreement or the other
Definitive Documents, in each case, in accordance with the terms hereof and thereof. To the Company’s Knowledge, no facts or circumstances
exist which might prevent the Company or any of its Subsidiaries from obtaining or effecting any of the registrations, applications or
filings contemplated by the Definitive Documents. The Company is not in violation of the requirements of the NYSE American and has no
Knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of the Common Stock.

 

Section 3.6     No
General Solicitation; Agents’ Fees. Neither the Company, nor any of its Subsidiaries, Affiliates, Representatives or any other
Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with the offer or sale of the Securities. Except for the amount payable to Ladenburg Thalmann & Co. Inc. or
any of its Affiliates which has been conveyed to the Purchaser in writing prior to the date of this Agreement, no placement agent’s
fees, financial advisory fees, or brokers’ commissions or fees or any similar fees are or will be owed or payable to any Person
in connection with transactions contemplated by the Definitive Documents. Neither the Company nor any of its Subsidiaries has engaged
any placement agent or other agent in connection with the offer or sale of the Securities. The Company further acknowledges that Purchaser
is not acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect
to the Definitive Documents and the transactions contemplated thereby and that the Company’s decision to enter into the Definitive
Documents to which it is a party has been based solely on the independent evaluation by the Company and its Representatives.

 

Section 3.7     Application
of Takeover Protections; Rights Agreement; Other Approvals. The Company and the Board have taken all necessary actions, if any, in order
to comply with or obtain waivers in connection with any control share acquisition, interested stockholder, business combination, poison
pill (including any distribution under a rights agreement), stockholder rights plan or other similar anti-takeover provision under any
of the Group Companies Organizational Documents or the Laws of the jurisdiction of its incorporation or otherwise which is or could become
applicable to Stockholders as a result of the transactions contemplated by the Definitive Documents, including the Company’s issuance
of the Securities and ownership by the Purchaser of the Securities, or as a result of the Purchaser acquiring the Common Stock, 2020
Warrants and/or 2021 Warrants (and the Common Stock issuable upon exercise thereof) issued under the 2020 Purchase Agreement and 2021
Purchase Agreements, respectively. The Company and the Board have taken all necessary action, if any, in order to render inapplicable
any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of shares of Common Stock or a change
in control of the Company or any of its Subsidiaries. The Company and the Board have taken all necessary action in order to exempt the
acquisition of the Purchased Common Stock, the Purchased Warrants (and the Common Stock issuable upon exercise thereof), the Common Stock
Purchased pursuant to the 2020 Purchase Agreement, the 2020 Warrants (and the Common Stock issuable upon exercise thereof), the Common
Stock Purchased pursuant to the 2021 Purchase Agreements, and the 2021 Warrants (and the Common Stock issuable upon exercise thereof)
from Section 16(b) of the Securities Exchange Act of 1934 (the “1934 Act”), including pursuant to Rule 16b-3(d).

 

     14

     

    

 

Section 3.8     SEC
Documents; Financial Statements.

 

(a)            The
Company (including its predecessors) has timely filed all reports, schedules, forms, proxy statements, statements and other documents
required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act or the Securities Act (all of the foregoing
filed since January 1, 2018 and all exhibits and appendices included therein and financial statements, notes and schedules thereto
and documents incorporated by reference therein being hereinafter referred to as the “SEC Documents”). The Company
has delivered or has made available to Purchaser true, correct and complete copies of each of the SEC Documents not available on the EDGAR
system. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act, the rules and
regulations of the SEC promulgated thereunder and the rules and regulations of the NYSE American, in each case, applicable to the
SEC Documents, and none of the SEC Documents contains any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. None of the Company’s Subsidiaries is subject to the periodic reporting requirements of the 1934 Act. There are
no outstanding or unresolved comments in comment letters from the SEC staff with respect to any of the SEC Documents. To the Company’s
Knowledge, no SEC Document is the subject of ongoing SEC review or outstanding SEC investigation.

 

(b)            As
of their respective dates, the audited and unaudited financial statements of the Company and its predecessors included in the SEC Documents
(including, in each case, the notes thereto, the “Financial Statements”), complied in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing.
The Financial Statements have been prepared in accordance with GAAP (except (i) as may be otherwise indicated in such Financial Statements
or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed
or summary statements), and fairly present in all material respects the financial position of the Company as of the dates thereof and
the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end
audit adjustments which will not be material, either individually or in the aggregate). The Company is not currently contemplating to
amend or restate any of the Financial Statements (including any notes or any letter of the independent accountants of the Company with
respect thereto), nor, to the Company’s Knowledge, do there exist any facts or circumstances which would require the Company to
amend or restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance with
GAAP and the rules and regulations of the SEC. The Company has not been informed by its independent accountants that they recommend
that the Company amend or restate any of the Financial Statements or that there is any need for the Company to amend or restate any of
the Financial Statements.

 

     15

     

    

 

(c)            The
Company and each of its Subsidiaries maintains internal control over financial reporting (as such term is defined in Rule 13a-15(f) under
the 1934 Act) that are effective to provide reasonable assurances regarding the reliability of the financial reporting and the preparation
of financial statements of the Company and its Subsidiaries for external purposes in accordance with GAAP, and includes those policies
and procedures that (i)  pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions
and dispositions of the assets of the Company, (ii) transactions are recorded as necessary to permit preparation of financial statements
and (iii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements
in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management
and directors of the Company. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under
the 1934 Act) that are effective in ensuring that information required to be disclosed by the Company in the reports that it files or
submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms
of the SEC, including controls and procedures designed to ensure that information required to be disclosed by the Company in the reports
that it files or submits under the 1934 Act is accumulated and communicated to the Company’s management, including its principal
executive officer or officers and its principal financial officer or officers, as appropriate, to allow timely decisions regarding required
disclosure. Neither the Company nor any of its Subsidiaries has received any notice or correspondence from any accountants, Governmental
Entities or other Person relating to (x) any potential material weakness or significant deficiency in any part of the internal controls
over financial reporting of the Company or any of its Subsidiaries or (y) any fraud, whether or not material, that involves (or involved)
the management or other employees of the Company or its Subsidiaries who have (or had) a significant role in the Company’s or its
Subsidiaries’ internal controls.

 

(d)            There
is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries and an unconsolidated or other off
balance sheet entity that is required to be disclosed by the Company in its 1934 Act filings and is not so disclosed or that otherwise
would have a Material Adverse Effect.

 

(e)            There
are no material disagreements of any kind presently existing or, to the Company’s Knowledge, reasonably anticipated to arise between
the Company and any of its Subsidiaries, on the one hand, and the accountants and lawyers formerly or presently employed by the Company
(including its predecessors) and any of Subsidiaries thereof, on the other hand, and the Company and each of its Subsidiaries is current
with respect to any fees owed to its respective accountants and lawyers which, the failure to pay could affect the Company’s ability
to perform any of its obligations under any of the Definitive Documents.

 

Section 3.9     Absence
of Certain Changes. Since December 31, 2020 (the “10-K Date”), and other than as disclosed in the SEC Documents,
there has been no material adverse change and no material adverse development in the business, assets, liabilities, properties, operations
(including results thereof), condition (financial or otherwise) or prospects of the Company or any of its Subsidiaries taken as a whole.
Since the 10-K Date, neither the Company nor any of its Subsidiaries has taken any action that if taken after the date hereof would require
the consent of the Purchaser pursuant to Section 5.1(b). Neither the Company nor any of its Subsidiaries has taken any steps
to seek protection pursuant to any applicable Law relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding
up, nor does the Company or any Subsidiary have any Knowledge or reason to believe that any of their respective creditors intend to initiate
involuntary bankruptcy proceedings or any Knowledge of any fact which would reasonably lead a creditor to do so. The Company and its
Subsidiaries, individually and on a consolidated basis, are not as of the date hereof, and, after giving effect to the transactions contemplated
by the Definitive Documents, will not be, Insolvent. Neither the Company nor any of its Subsidiaries has engaged in any business
or in any transaction, and does not plan to engage in any business or in any transaction, for which the Company’s or such Subsidiary’s
remaining assets constitute unreasonably small capital with which to conduct the business in which it is engaged as such business is
now conducted and is proposed to be conducted.

 

     16

     

    

 

Section 3.10     Conduct
of Business; Regulatory Permits.

 

(a)            Neither
the Company nor any of its Subsidiaries is in violation of any term of or in default under the Group Companies Organizational Documents.
Neither the Company (including its predecessors) nor any Subsidiaries thereof (i) is, or has been since January 1, 2019, in
violation of any applicable Law or Order applicable thereto or (ii) has received since January 1, 2019 a notification or communication
from any Governmental Entity asserting that it is not or has not been in compliance with any applicable Law or Order. Without limiting
the generality of the foregoing, the Company is not in material violation of any of the rules, regulations or requirements of the NYSE
American, and has no Knowledge of any facts or circumstances that could reasonably lead to delisting or suspension of trading the Common
Stock by the NYSE American. Since January 1, 2019, (i) the Common Stock has been listed or designated for quotation on the NYSE
American, (ii) trading in the Common Stock has not been suspended by the SEC or the NYSE American and (iii) the Company has
received no communication, written or oral, from the SEC or the NYSE American regarding the suspension or delisting of the Common Stock
from the NYSE American. The Company and each of its Subsidiaries possess all licenses, certificates, authorizations and permits issued
by the appropriate Governmental Entity necessary to conduct their respective businesses, and neither the Company nor any such Subsidiary
has received any notice of proceedings relating to the revocation or modification of any such license, certificate, authorization or permit.
There is no Contract or Order binding upon the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is
a party which, individually or together with any other Contract or Order, has had or would reasonably be expected to have the effect of
prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the
Company or any of its Subsidiaries.

 

(b)            The
Common Stock is registered pursuant to Section 12(b) or 12(g) of the 1934 Act, and the Company has taken no action designed
to, or which to its Knowledge is likely to have the effect of, terminating the registration of the Common Stock under the 1934 Act nor
has the Company received any notification that the SEC is contemplating terminating such registration. The Company has not, since January 1,
2021, received notice from the NYSE American to the effect that the Company is not in compliance with the listing or maintenance requirements
of the NYSE American. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance
with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository
Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.

 

     17

     

    

 

Section 3.11     Certain
Regulatory Matters.

 

(a)            None
of the Company (including its predecessors), any Subsidiaries thereof or any of their respective directors, officers, or other Representatives
(individually and collectively, a “Company Affiliate”) have violated the U.S. Foreign Corrupt Practices Act (the “FCPA”)
or any other applicable anti-bribery or anti-corruption Law, nor has any Company Affiliate offered, paid, promised to pay, or authorized
the payment of, any money, or offered, given, promised to give, or authorized the giving of, anything of value, to any officer, employee
or any other person acting in an official capacity for any Governmental Entity or any political party or official thereof or to any candidate
for political office (individually and collectively, a “Government Official”) or to any Person under circumstances
in which such Company Affiliate knew or was aware of a high probability that all or a portion of such money or thing of value would be
offered, given or promised, directly or indirectly, to any Government Official, for the purpose of: (i) (A) influencing any
act or decision of such Government Official in his/her official capacity, (B) inducing such Government Official to do or omit to
do any act in violation of his/her lawful duty, (C) securing any improper advantage, or (D) inducing such Government Official
to influence or affect any act or decision of any Governmental Entity; or (ii) assisting the Company or its Subsidiaries in obtaining
or retaining business for or with, or directing business to, the Company or its Subsidiaries.

 

(b)            The
Company has in place policies, procedures and controls that ensure compliance with the (i) FCPA and (ii) other applicable anti-bribery
or anti-corruption laundering Laws in each foreign jurisdiction in which the Company does business.

 

(c)            No
Company Affiliates or any other business entity or enterprise with which the Company or any Subsidiary is or has been Affiliated or associated,
has, directly or indirectly, made or authorized any payment, contribution or gift of money, property, or services, whether or not in contravention
of applicable Law, (i) as a kickback, bribe gratuity, lobbying expenditure, political contribution or contingent fee payment to any
Person or (ii) to any political organization, or to the holder of or any aspirant to any elective or appointive public office except
for personal political contributions not involving the direct or indirect use of funds of the Company or any of its Subsidiaries.

 

(d)            The
Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act of 2001 and all other applicable
U.S. and non-U.S. anti-money laundering Laws and regulations and Sanctions, including the Laws, executive orders and sanctions programs
administered by OFAC. No Company Affiliates (x) is a Sanctioned Person or has any reason to believe that it is acting on behalf of,
or for the benefit of, any Sanctioned Person or (y) has engaged in any dealings with or the benefit of any Sanctioned Person, or
in or involving any Sanctioned Country.

 

(e)            Since
January 1, 2019, no allegations of sexual harassment have been made to the Company (including its predecessors) or any Subsidiaries
thereof against any individual in his or her capacity as director or a managerial employee, or to the Company’s Knowledge, any other
employee, of the Company (including its predecessors) or any Subsidiaries thereof.

 

Section 3.12     Sarbanes-Oxley
Act. The Company and each of its Subsidiaries is in material compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002, as amended, and any and all applicable rules and regulations promulgated by the SEC thereunder.

 

     18

     

    

 

Section 3.13     Transactions
With Affiliates. There have not been any transactions or Contracts or series of related transactions or Contracts required to be disclosed
under Item 404 of Regulation S-K under the 1934 Act.

 

Section 3.14     Capitalization

 

(a)            As
of the date hereof, the authorized capital stock of the Company consists of 217,000,000 shares of Common Stock, of which 27,112,299 are
issued and outstanding. No shares of Common Stock are held in the treasury of the Company. Except for the foregoing Capital Stock, the
Company has no other Capital Stock authorized. The Company also has reserved for issuance 2,439,682 shares of Common Stock issuable upon
exercise of outstanding stock options, and 16,647,219 shares of Common Stock issuable upon exercise of outstanding warrants.

 

(b)            All
of the Company’s Capital Stock is duly authorized and validly issued, fully paid and non-assessable (as such concepts are applicable).
All the outstanding shares of Capital Stock of each Subsidiary of the Company have been validly issued and are fully paid and non-assessable
(to the extent such concepts are applicable) and are owned, directly or indirectly, by the Company free and clear of all Liens.

 

(c)            (A) None
of the Company’s or any of its Subsidiaries’ Capital Stock is subject to preemptive rights or any other similar rights or
restrictions or Liens suffered or permitted by the Company or any Subsidiary; (B) other than the 2020 Warrants, 2021 Warrants, and
as of the Second Closing, other than the Purchased Warrants issued to the Purchaser on the First Closing, there are no outstanding options,
warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, or exercisable or exchangeable for, any Capital Stock of the Company or any of its Subsidiaries, or Contracts by which the Company
or any of its Subsidiaries is or may become bound to issue additional Capital Stock of the Company or any of its Subsidiaries or options,
warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, or exercisable or exchangeable for, any Capital Stock of the Company or any of its Subsidiaries; (C) other than Registration
Rights Agreement, there are no Contracts under which the Company or any of its Subsidiaries is obligated to register the sale of any of
their securities under the Securities Act; (D) there are no outstanding securities or instruments of the Company or any of its Subsidiaries
which contain any redemption or similar provisions, and there are no Contracts, commitments, understandings or arrangements by which the
Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (E) there
are no securities or instruments or Capital Stock containing anti-dilution or similar provisions that will be triggered by the issuance
of the Securities; (F) neither the Company nor any Subsidiary has any stock appreciation rights or “phantom stock” plans
or agreements or any similar plan or agreement; and (G) other than the Voting Agreement, there are no stockholder agreements, voting
trusts or other agreements to which the Company or any of its Subsidiaries is a party or by they are bound relating to the voting of any
shares, interests or capital stock of the Company or any of its Subsidiaries.

 

(d)            True,
correct and complete copies of the Company Organizational Documents, and the terms of all convertible securities and the material rights
of the holders thereof in respect thereto, are set forth in, or filed as exhibits to the SEC Documents.

 

     19

     

    

 

Section 3.15     Indebtedness.
Neither the Company nor any of its Subsidiaries has any outstanding Indebtedness.

 

Section 3.16     Material
Contracts. Neither the Company nor any of its Subsidiaries is party to, and none of their respective properties or assets are bound by,
a Material Contract. Each Material Contract set forth in the SEC Documents is in full force and effect, and is a legal, valid and binding
agreement of the Company or its Subsidiaries, as applicable, and, to the Company’s Knowledge, the other parties thereto, subject
only to the General Enforceability Exceptions. There is no material default or breach by the Company or any of its Subsidiaries, as applicable,
with respect to any such Material Contract or, to the Company’s Knowledge, any other party thereto, and no event has occurred which,
with notice or lapse of time or both, would constitute a material breach or default or would permit termination, material modification
or acceleration thereof by any party to such Material Contract. Neither the Company nor any of its Subsidiaries has waived any material
rights under any such Material Contract. Neither the Company nor any of its Subsidiaries has received written notice of the intention
of any third party under any such Material Contract to cancel, terminate or materially modify the terms of any such Material Contract,
or accelerate the obligations of the Company or any of its Subsidiaries, as applicable, thereunder. There are no current or pending financing
arrangements or assignments of proceeds with respect to any such Material Contract.

 

Section 3.17     Litigation.
Except as would not, individually or in the aggregate, have a Material Adverse Effect, there is no, and since January 1, 2019 there
has not been, any Action before or by the NYSE American, any court, public board, other Governmental Entity, self-regulatory organization
or body pending or, to the Knowledge of the Company, threatened against or affecting the Company (including its predecessors) or any
of Subsidiaries thereof, the Capital Stock thereof or any current or former officers, directors, managers or employees thereof, whether
of a civil or criminal nature or otherwise, in their capacities as such. To the Knowledge of the Company, no current or former director,
officer, manager or employee of the Company (including its predecessors) or any of its Subsidiaries has willfully violated 18 U.S.C.
 § 1519 or engaged in spoliation in reasonable anticipation of litigation. Without limitation of the foregoing, there has not been,
and to the Knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company (including
its predecessors), any Subsidiaries thereof or any current or former director, officer, manager of employee of the Company or any of
its Subsidiaries. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company under the Securities Act or the 1934 Act. To the Company’s Knowledge, no fact exists which might result in or form
the basis for any such Action. Neither the Company nor any of its Subsidiaries is subject to any Order.

 

Section 3.18     Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts, in each case, as is customary in the businesses in which the Company and its Subsidiaries are engaged. All premiums
due and payable in respect of such insurance policies maintained by the Company and its Subsidiaries have been paid in full. Neither
the Company nor any of its Subsidiaries have been refused any insurance coverage sought or applied for, and neither the Company nor any
such Subsidiary has any reason to believe that it will be unable to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business on substantially the same terms as now
in effect. Excluding insurance policies that have expired and been replaced in the ordinary course of business, no such insurance policy
of the Company or any of its Subsidiaries has been, or has been threatened to be, cancelled by the applicable insurer since January 1,
2019, and neither the Company nor any of its Subsidiaries has received any written notice of cancellation or non-renewal of any such
insurance policy.

 

     20

     

    

 

Section 3.19     Employee
Relations. The Company and each of its Subsidiaries maintains good relationships with their respective employees. No executive officer
(as defined in Rule 501(f) promulgated under the Securities Act) or other key employee of the Company or any of its Subsidiaries
has notified the Company or the applicable Subsidiary that such executive officer or key employee intends to terminate, or materially
amend the terms of, its employment with the Company or the applicable Subsidiary. To the Company’s Knowledge, no executive officer
or other key employee of the Company or any of its Subsidiaries is or will be (with or without the passage of time, or both), in violation
of any material term of any employment Contract, confidentiality, disclosure or proprietary information Contract, non-competition Contract
or any other Contract, or any restrictive covenant, and the continued employment of each such executive officer or other key employee
(as the case may be) does not subject the Company or any of its Subsidiaries to any material liability with respect to any of the foregoing
matters. The Company and its Subsidiaries are in compliance with all applicable federal, state, local and foreign Laws respecting labor,
employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be
in compliance would not, either individually or in the aggregate, result in a Material Adverse Effect. There are no strikes or other
labor disputes against the Company or any of its Subsidiaries, and, to the Knowledge of the Company, there are no strikes or other labor
disputes threatened against the Company or any of its Subsidiaries.

 

Section 3.20     Title.

 

(a)            The
Company and each of its Subsidiaries holds good title to all real property, leases in real property, facilities or other interests in
real property owned or held by the Company or any of its Subsidiaries, as applicable (the “Real Property”). The Real
Property is free and clear of all Liens and is not subject to any rights of way, building use restrictions, exceptions, variances, reservations,
or limitations of any nature except for (a) Liens for current Taxes not yet due for which adequate reserves (as determined in accordance
with the GAAP) have been established on the Financial Statements, (b) zoning Laws and other land use restrictions that do not, and
will not (with or without the passage of time, or both) impair the present or anticipated use of the Real Property subject thereto, and
(c) mechanics’, carriers’, workmen’s, warehousemen’s, repairmen’s or other statutory liens arising
in the ordinary course of business that would not reasonably be expected to have a Material Adverse Effect. Each Real Property held under
lease by the Company or any of its Subsidiaries is held by the Company or its applicable Subsidiary under a valid, subsisting and enforceable
leases with such exceptions as are not material and do not interfere with the current and anticipated use made and proposed to be made
of such Real Property and buildings by the Company or any of its Subsidiaries, as applicable.

 

(b)            Each
of the Company and its Subsidiaries (as applicable) has good title to, or a valid leasehold interest in, the tangible personal property,
equipment, improvements, fixtures, and other personal property and appurtenances that are used by the Company or its Subsidiary in connection
with the conduct of its business (the “Fixtures and Equipment”). The Fixtures and Equipment are structurally sound,
are in good operating condition and repair, are adequate for the uses to which they are being put, are not in need of maintenance or repairs,
except for routine maintenance and repairs in the ordinary course of business, and are sufficient, in all material respects, for the conduct
of the Company’s and its Subsidiaries’ businesses as currently conducted. The Company and its Subsidiaries collective own
all of the Fixtures and Equipment free and clear of all Liens except for (a) Liens for current Taxes not yet due for which adequate
reserves (as determined in accordance with GAAP) have been established on the Financial Statements, (b) zoning Laws and other land
use restrictions that do not impair the present or anticipated use of the Fixtures and Equipment subject thereto, (c) mechanics’,
carriers’, workmen’s, warehousemen’s, repairmen’s or other statutory liens arising in the ordinary course of business
that would not reasonably be expected to have a Material Adverse Effect and (d) minor liens that have arisen in the ordinary course
of business and that do not, individually or in the aggregate, materially detract from the value of the assets or properties subject thereto
or materially impair the operations of the Company or its any of Subsidiaries.

 

     21

     

    

 

Section 3.21     Intellectual
Property Rights.

 

(a)            The
Company and its Subsidiaries collectively own or possess good and marketable title to, or valid licenses to use, all trademarks, trade
names, service marks, service mark registrations, service names, original works of authorship, patents, patent rights, copyrights, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and registrations
therefor (“Intellectual Property Rights”) necessary to conduct their respective businesses as now conducted and presently
proposed to be conducted in all material respects. None of the Company’s material Intellectual Property Rights have expired or have
been terminated or abandoned, or are expected to expire, or to be terminated or abandoned, in each case, within three (3) years from
the date of the Agreement. The Company does not have any Knowledge of any infringement, misappropriate or violation by the Company or
its Subsidiaries of Intellectual Property Rights of others.

 

(b)            The
Company is the exclusive owner of the entire right, title and interest in and to AP-SA02, and is the exclusive owner of the entire right,
title and interest in and to, or has licensed or has the right to license all Intellectual Property rights in, AP-PA02 (collectively,
the “Products”), all data associated therewith, and all Intellectual Property Rights covering or relating to the Products,
free and clear of all liens. To the Company’s Knowledge, all patents owned or controlled by the Company that have been issued or
granted by the appropriate Patent Office are valid and enforceable.

 

(c)            There
is no Action which has been brought, or to the Knowledge of the Company, being threatened, against the Company or any of its Subsidiaries
regarding its Intellectual Property Rights. To the Knowledge of the Company, there are no facts or circumstances which might give rise
to any Actions regarding the Company’s Intellectual Property Rights.

 

(d)            To
the Company’s Knowledge, the manufacture, use, offer for sale, sale and/or importation of any of the Products will not infringe
and patent or other Intellectual Property Rights of any third party. Neither Company nor any of its Subsidiaries has received written
or oral notice of any Action that claims that the development, manufacture, use, marketing, sale, offer for sale, importation or distribution
of any Product would infringe on Intellectual Property Rights of any third party.

 

     22

     

    

 

(e)            The
Company is in material compliance with all terms of and obligations under its collaboration agreement with Merck and its grant agreements
with the National Institute of Health and the National Institute of Allergy and Infectious Diseases, and has not breached and is not in
default under any provision of those agreements.

 

(f)            No
event has occurred that would give Merck the right to unilaterally terminate the collaboration agreement. The Company has not received
any notice of an intention by Merck to terminate the collaboration agreement, and the Company has not agreed with Merck to terminate the
collaboration agreement in whole or in part.

 

(g)            The
Company is in material compliance with all healthcare laws and regulations, and with the codes of conduct published by the Pharmaceutical
Research and Manufacturers of America.

 

(h)            The
Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their
Intellectual Property Rights. In the past five years, the Company and its Subsidiaries have not (i) experienced any actual, alleged,
or suspected data breach or other security incident or (ii) been subject to or received any notice of any audit, investigation, complaint,
or other claim concerning the violation of any data protection laws.

 

Section 3.22     Environmental
Laws.

 

(a)            The
Company (including its predecessors) and Subsidiaries thereof (A) are, and since January 1, 2018 have been, in compliance with
any and all Environmental Laws (as defined below), and neither the Company nor any of its Subsidiaries has received any written communication
alleging that the Company is in violation of, or has any liability under, any Environmental Law, (B) have received all permits, licenses
or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (C) are in compliance
with all terms and conditions of any such permit, license or approval where, in each of the foregoing clauses (A), (B) and (C), the
failure to so comply would not have, individually or in the aggregate, a Material Adverse Effect.

 

(b)            No
Hazardous Materials (i) have been disposed of or otherwise released from any currently or formerly owned Real Property of the Company
(including its predecessors) or any Subsidiaries thereof in violation of any Environmental Laws; and (ii) are, to the Company’s
Knowledge, present on, over, beneath, in or upon any Real Property or any portion thereof in quantities that would constitute a violation
of any Environmental Laws.

 

Section 3.23     Tax
Status. The Company and each of its Subsidiaries (i) has timely made or filed all Tax Returns required by any jurisdiction to which
it is subject, (ii) has timely paid all Taxes and other governmental assessments and charges (including satisfying its withholding
tax obligations) levied or imposed on their properties, income or assets or otherwise due and payable, except those being contested in
good faith for which adequate reserves (as determined in accordance with the GAAP) have been established on the Financial Statements
and (iii) has set aside on its books provision reasonably adequate for the payment of all Taxes for periods subsequent to the periods
to which such Tax Returns apply. There are no unpaid Taxes claimed to be due and payable by the Taxing authority of any jurisdiction,
and, to Knowledge of the Company, no facts or circumstances exist of that would be the basis for any such claim. The Company is not operated
in such a manner as to qualify as a passive foreign investment company, as defined in Section 1297 of the Internal Revenue Code
of 1986, as amended (the “Code”).

 

     23

     

    

 

Section 3.24     Investment
Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an “investment company,”
an affiliate of an “investment company,” a company controlled by an “investment company” or an “affiliated
person” of, or “promoter” or “principal underwriter” for, an “investment company” as such terms
are defined in the Investment Company Act of 1940, as amended.

 

Section 3.25     U.S.
Real Property Holding Corporation. The Company (including its predecessors) and all Subsidiaries thereof is not, has not ever been, and,
for so long as any of the Securities are held by the Purchaser, shall not become, a U.S. real property holding corporation within the
meaning of Section 897 of the Code.

 

Section 3.26     Registration
Eligibility. The Company is, and from and after the date hereof will be, eligible to register the Registrable Securities (as defined
in the Registration Rights Agreement) for resale by the Purchaser using Form S-1 or Form S-3 promulgated under the 1933 Act.

 

Section 3.27     Transfer
Taxes. On the Second Closing Date, all stock transfer or other Taxes (other than income or similar Taxes) which are required to be paid
in connection with the issuance, sale and transfer of the Securities to be sold to Purchaser pursuant to this Agreement will be, or will
have been, fully paid or provided for by the Company, and all Laws imposing such Taxes will be or will have been complied with in all
material respects.

 

Section 3.28     Shell
Company Status. The Company is not an issuer identified in, and subject to, Rule 144(i).

 

Section 3.29     ERISA
Compliance.

 

(a)            Each
Plan is in material compliance with the applicable provisions of ERISA, the Code and other applicable federal or state Laws.

 

(b)            (i) No
ERISA Event has occurred for which the Company, any of its Subsidiaries or any of their respective ERISA Affiliates has any residual liability;
and (ii) no ERISA Event is expected to occur, except as would not reasonably be expected, individually or in the aggregate, to result
in a material adverse effect on the Company and its Subsidiaries taken as a whole.

 

(c)            At
no time during the past six (6) years has the Company (including its predecessors) or any member of the “Controlled Group”
thereof (defined as any organization which is a member of a controlled group of organizations within the meaning of Code Sections 414(b),
(c), (m) or (o)) maintained, sponsored or contributed to, or been obligated to contribute to (i) any retirement plan which is
subject to Title IV of ERISA or Section 412 of the Code or (ii) any “multiemployer plan” as defined in Section 4001(a)(3) of
ERISA

 

     24

     

    

 

Section 3.30     Management.
Since January 1, 2019, no current or former officer or director or, to the Knowledge of the Company, no current ten percent (10%)
or greater stockholder of the Company (including its predecessors) or any Subsidiaries thereof has been the subject of:

 

(a)            a
petition under applicable bankruptcy Laws or any other applicable insolvency or moratorium Law or the appointment by a court of a receiver,
fiscal agent or similar officer for such Person, or any partnership in which such person was a general partner, or any corporation or
business association of which such person was an executive officer;

 

(b)            a
conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations that do not relate
to driving while intoxicated or driving under the influence);

 

(c)            any
Order that has not subsequently reversed, suspended or vacated, permanently or temporarily enjoining any such person from, or otherwise
limiting, the following activities:

 

(i)            engaging
in any particular type of business practice; or

 

(ii)            engaging
in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of securities
Laws or commodities Laws;

 

(d)            any
Order that has not been subsequently reversed, suspended or vacated, barring, suspending or otherwise limiting for more than sixty (60)
days the right of any such person to engage in any activity described in the preceding sub paragraph, or to be associated with persons
engaged in any such activity;

 

(e)            a
finding by a Governmental Entity in a civil Action or by the SEC or other authority to have violated any securities Laws or decrees, and
the judgment in such civil Action or finding by the SEC or any other authority has not been subsequently reversed, suspended or vacated;
or

 

(f)            a
finding by a Governmental Entity in a civil Action or by the Commodity Futures Trading Commission to have violated any federal commodities
Laws, and the judgment in such civil Action or finding has not been subsequently reversed, suspended or vacated.

 

Section 3.31     FDA.
There is no pending, completed or, to the Company’s Knowledge, threatened, Action or investigation against the Company or any of
its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from
the U.S. Food and Drug Administration (“FDA”) or any other governmental entity, which (i) contests the premarket
clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing
of, the sale of, or the labeling and promotion of any Product, (ii) withdraws its approval of, requests the recall, suspension,
or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Product, (iii) imposes
a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility
of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the
Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company
or any of its Subsidiaries. The properties, business and operations of the Company have been and are being conducted in all material
respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA
that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced
or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed
or proposed to be developed by the Company.

 

     25

     

    

 

Section 3.32     Stock
Option Plans. Each stock option granted by the Company was granted (i) in accordance with the terms of the applicable stock option
plan of the Company and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such
stock option would be considered granted under GAAP and applicable Law. No stock option granted under the Company’s stock option
plan has been backdated. The Company has not granted, nor has there been any policy or practice of the Company to knowingly grant, stock
options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material
information regarding the Company or its Subsidiaries or their financial results or prospects.

 

Section 3.33     No
Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the Securities
Act (“Regulation D Securities”), none of the Company, any of its predecessors, any Affiliated issuer, any director,
executive officer, other officer of the Company participating in the offering of the Securities contemplated by this Agreement, or to
the Company’s Knowledge, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated
on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the
Company in any capacity at the time of sale (each, an “Issuer Covered Person” and, together, “Issuer Covered
Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under
the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or
(d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event.
The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to Purchaser
a copy of any disclosures provided thereunder. The Company is not aware of any Person that has been or will be paid (directly or indirectly)
remuneration for solicitation of Purchaser or other potential purchasers in connection with the sale of the Securities contemplated by
this Agreement.

 

Section 3.34     No
Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in this Agreement, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration
of any such securities under the Securities Act, or (ii) any applicable stockholder approval provisions of the NYSE American.

 

     26

     

    

 

Section 3.35     Regulation
M Compliance. The Company has not, and to its Knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any
action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of,
any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company.

  

Section 3.36     Disclosure.
The Company understands and confirms that Purchaser will and is entitled to rely on the foregoing representations in effecting transactions
in securities of the Company. All disclosure provided to Purchaser regarding the Company and its Subsidiaries, their businesses and the
transactions contemplated by the Definitive Documents furnished by or on behalf of the Company or any of its Subsidiaries does not contain
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in
the light of the circumstances under which they were made, misleading. No event or circumstance has occurred and no information exists
with respect to the Company or any of its Subsidiaries or its or their business, properties, liabilities, prospects, operations (including
results thereof) or conditions (financial or otherwise), which, under applicable Law, requires public disclosure at or before the date
hereof or announcement by the Company but which has not been so publicly disclosed. All financial projections and forecasts that have
been prepared by or on behalf of the Company or any of its Subsidiaries and made available to Purchaser have been prepared in good faith
based upon reasonable assumptions and represented, at the time each such financial projection or forecast was delivered to Purchaser,
the Company’s best estimate of future financial performance (it being recognized that such financial projections or forecasts are
not to be viewed as facts and that the actual results during the period or periods covered by any such financial projections or forecasts
may differ from the projected or forecasted results).

 

Section 3.37     Proxy
Statement. None of the information in the Proxy Statement to be sent to the stockholders of the Company in connection with the Company
Stockholders’ Meeting will, on the date it is filed, on the date it is first mailed to the stockholders of the Company and at the
time of the Company Stockholders’ Meeting, contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made,
not misleading. The Proxy Statement will, at the time of the Company Stockholders’ Meeting, comply as to form in all material respects
with the requirements of the 1934 Act and the rules and regulations promulgated thereunder.

 

Section 3.38     Disclaimer
of Other Representations and Warranties. Except as expressly set forth in this Article III or in any other Definitive Document,
the Company makes no representation or warranty, express or implied, at law or in equity, including with respect to it or any of its
Subsidiaries or any of their respective assets, liabilities or operations, and any such other representations and warranties are hereby
expressly disclaimed.

 

     27

     

    

 

Article IV

 

REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

 

Purchaser hereby represents
and warrants as of the date hereof, as of the First Closing, and as of the Second Closing, as follows:

 

Section 4.1     Organization.
Purchaser is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Delaware.

 

Section 4.2     Organizational
Power and Authority. Purchaser has the requisite power and authority to enter into, execute and deliver this Agreement and to perform
its obligations hereunder and has taken or will take all necessary corporate action required for the due authorization, execution, delivery
and performance by it of this Agreement and the transactions contemplated hereby.

 

Section 4.3     Execution
and Delivery. This Agreement has been validly executed and delivered by Purchaser, and, assuming due and valid execution and delivery
hereof by the Company, will constitute valid and legally binding obligations of Purchaser, enforceable against Purchaser in accordance
with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization or other similar Laws limiting creditors’
rights generally or by equitable remedies (regardless of whether enforceability is considered in a proceeding at law or in equity).

 

Section 4.4     No
Conflict. The execution and delivery by Purchaser of this Agreement and the consummation of the transactions contemplated hereby (a) will
not conflict with, or result in a breach, modification, termination or violation of, any of the terms or provisions of, or constitute
a default under (with or without notice or lapse of time or both), or result in the acceleration of, or the creation of any Lien under,
any Contract to which Purchaser is party or is bound or to which any of the property or assets of Purchaser are subject, (b) will
not result in any violation of the provisions of the certificate of formation or limited liability company agreement of Purchaser, and
(c) will not result in any material violation of any Law or Order applicable to Purchaser or any of its properties, except in each
of the cases described in clauses (a) through (c), for any conflict, breach, modification, termination, violation, default,
acceleration or Lien which would not reasonably be expected, individually or in the aggregate, to prohibit or materially and adversely
impact Purchaser’s performance of its obligations under this Agreement.

 

Section 4.5     Consents
and Approvals. No consent, approval, authorization, Order, registration or qualification of or with any Governmental Entity having jurisdiction
over Purchaser or any of its properties is required for the execution and delivery by Purchaser of this Agreement, the compliance by
Purchaser with the provisions hereof and the consummation of the transactions contemplated hereby, except any consent, approval, authorization,
Order, registration or qualification which, if not made or obtained, would not reasonably be expected, individually or in the aggregate,
to prohibit or materially and adversely impact Purchaser’s performance of its obligations under this Agreement.

 

Section 4.6     No
Registration. Purchaser understands that (a) the Purchased Common Stock and Purchased Warrants (including any shares of Common Stock
issuable upon exercise thereof) have not been registered under the Securities Act by reason of a specific exemption or exclusion from
the registration provisions of the Securities Act, the availability of which depends on, among other things, the bona fide nature of
the investment intent and the accuracy of Purchaser’s representations as expressed herein or otherwise made pursuant hereto and
(b) the foregoing securities cannot be sold unless subsequently registered under the Securities Act or an exemption or exclusion
from registration is available.

 

     28

     

    

 

Section 4.7     Purchasing
Intent. Purchaser is acquiring the Purchased Common Stock and Purchased Warrants (including any shares of Common Stock issuable upon
exercise thereof) for its own account or accounts or funds over which it or its Affiliates hold voting or investment discretion, not
otherwise as a nominee or agent, and not otherwise with the view to, or for resale in connection with, any distribution thereof not in
compliance with applicable securities Laws, and Purchaser has no present intention of selling, granting any other participation in, or
otherwise distributing the same, except in compliance with applicable securities Laws.

 

Section 4.8     Sophistication;
Investigation. Purchaser has such knowledge and experience in financial and business matters such that it is capable of evaluating the
merits and risks of its investment in the Purchased Common Stock and Purchased Warrants (including any shares of Common Stock issuable
upon exercise thereof). Purchaser is an “accredited investor” within the meaning of Rule 501(a) of the Securities
Act and an “institutional account” within the meaning of Rule 4512 of the Financial Industry Regulatory Authority or
a “qualified institutional buyer” within the meaning of Rule 144A of the Securities Act. Purchaser understands and is
able to bear any economic risks associated with such investment (including the necessity of holding such shares for an indefinite period
of time). Except for the representations and warranties expressly set forth in this Agreement, Purchaser has independently evaluated
the merits and risks of its decision to enter into this Agreement and consummate the transactions contemplated hereby.

 

Section 4.9     Sufficient
Funds. Purchaser has, or at the applicable Closing will have, sufficient assets and the financial capacity to perform all of its obligations
under this Agreement.

 

Section 4.10     Bad
Actor. Neither the Purchaser nor any person or entity with whom the Purchaser will share beneficial ownership of the Purchased Common
Stock is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under
the Securities Act.

 

Article V

 

ADDITIONAL COVENANTS

 

Section 5.1     Covenants
of the Company.

 

(a)            Affirmative
Covenants: Except (x) as otherwise expressly required by this Agreement, (y) as required by applicable Law or (z) as
consented to in writing by the Purchaser, during the period from the date hereof until the earliest of (i) the Second Closing, (ii) the
Second Closing Abandonment and (iii) the termination of this Agreement in accordance with Article VII, the Company shall,
and shall cause each of its direct and indirect Subsidiaries to:

 

(i)            preserve,
in all material respects, its business operations, organization and goodwill and its relationships with suppliers, customers, lenders
and others having business dealings with the Company and its Subsidiaries;

 

(ii)            to
the extent any legal or structural impediment arises that would prevent, hinder, or delay the consummation of the transactions contemplated
by this Agreement, support and take all steps reasonably necessary and desirable to address and resolve any such impediment;

 

     29

     

    

 

(iii)            use
good faith and commercially reasonable efforts to obtain all required Governmental Entity and third-party approvals for the consummation
of the transactions contemplated by this Agreement;

 

(iv)            inform
counsel to the Purchaser as soon as reasonably practicable after becoming aware of: (A) any Material Adverse Effect, (B) any
notice of any commencement of any involuntary insolvency proceedings, legal suit for payment of debt or securement of security from or
by any person in respect of the Company or any of its Subsidiaries, (C) a breach of this Agreement, and (D) any representation
or statement made or deemed to be made by the Company or any of its Subsidiaries under this Agreement, which is or proves to have been
materially incorrect or misleading in any respect when made or deemed to be made;

 

(v)            maintain
the good standing of the Company and any Subsidiaries of the Company under the Laws of the state or other jurisdiction in which they are
incorporated or organized;

 

(vi)            make
all necessary registrations, declarations and filings with, and notices to, Governmental Entities (including under the 1934 Act) (a) in
the ordinary course of business and (b) with respect to the transactions contemplated by this Agreement;

 

(vii)            operate
their business in the ordinary course of business; and

 

(viii)            provide,
and direct its Representatives to provide, to the Purchaser and its Representatives (A) reasonable access to the Company and its
Subsidiaries’ books and records during normal business hours on reasonable advance notice to the Company and its Subsidiaries’
Representatives, (B) reasonable access to the Representatives of the Company and its Subsidiaries on reasonable advance notice to
such persons, and (C) such other information as reasonably requested by the Purchaser and its Representatives.

 

(b)            Negative
Covenants: Except (x) as otherwise expressly required by this Agreement, (y) as required by applicable Law or (z) as
consented to by the Purchaser in writing, during the period from the date hereof until the earliest of (i) the Second Closing, (ii) the
Second Closing Abandonment and (iii) the termination of this Agreement in accordance with Article VII, the Company shall
not, and shall cause each of its direct and indirect Subsidiaries not to:

 

(i)            transfer
any material property, asset or right of the Company or its Subsidiaries or any material property, asset or right used in the business
of the Company and its Subsidiaries to any person or entity outside of the ordinary course of business;

 

     30

     

    

 

(ii)            engage
in any material disposition, acquisition, leasing, investment or other similar transaction (whether by merger, consolidation or otherwise)
outside of the ordinary course of business;

 

(iii)            incur,
create, assume, guarantee or otherwise become liable for any Indebtedness, other than trade indebtedness or contingent liabilities under
surety bonds, in each case, in the ordinary course of business;

 

(iv)            amend
the Company’s or any of its Subsidiaries’ organizational documents (whether by merger, consolidation or otherwise);

 

(v)            split,
combine, reclassify, redeem, repurchase, acquire, issue or deliver or amend the terms of any Capital Stock of the Company or any of its
Subsidiaries (whether by merger, consolidation or otherwise), other than the transactions expressly contemplated by this Agreement;

 

(vi)            enter
into any transactions with a Related Party;

 

(vii)            create
or incur any Lien on any capital stock, assets or properties of the Company or any of its Subsidiaries, other than (a) Liens related
to capital leases in place as of the date hereof or entered into after the date hereof in the ordinary course of business or (b) immaterial
Liens created or incurred in the ordinary course of business;

 

(viii)            adopt,
establish, enter into, amend, terminate or increase the benefits under any of the Company’s or its Subsidiaries’ benefit plans,
except for approval and adoption of annual compensation programs in the ordinary course of business;

 

(ix)            declare,
set aside, make or pay any dividend or other distribution (whether in stock, cash, other property or any combination thereof) with respect
to any Capital Stock of the Company and its Subsidiaries;

 

(x)            amend
or terminate any Material Contracts of the Company or its Subsidiaries, other than renewals, amendments, change orders and expirations
of such Material Contracts in the ordinary course of business;

 

(xi)            waive,
release, assign, settle or compromise any material action, suit, claim, cause of action, investigation, complaint, legal proceeding, administrative
enforcement proceeding, arbitration proceeding or other proceeding or adjudicative matter by or before any Governmental Entity (other
than actions in the ordinary course of business);

 

(xii)            settle
or compromise any material Tax Contest, consent to any extension or waiver of any limitation period with respect to any material claim
or assessment for Taxes, make, change or revoke any material Tax election or materially change any of the Company’s or its Subsidiaries’
accounting principles and methodologies (other than as required by GAAP); or

 

     31

     

    

 

(xiii)            agree,
commit or offer to do any of the foregoing.

 

Section 5.2     Pre-Closing
Exclusivity. From the date hereof until the earliest of (i) the Second Closing, (ii) the Second Closing Abandonment and (iii) the
termination of this Agreement in accordance with Article VII (provided, that, with respect to any termination of this Agreement
or the Second Closing Abandonment, the primary cause of which is the material breach by the Company of any of its covenants or other
agreements contained in this Agreement, the obligations under this Section 5.2 shall extend until 90 days following the earlier
of termination of this Agreement or the Second Closing Abandonment), (i) the Company shall not, and shall instruct its Affiliates
and Representatives not to, directly or indirectly, initiate, solicit, facilitate, encourage, discuss, negotiate, endorse, engage in,
enter into or accept any discussions, negotiations, proposals, inquiries, offers or agreements with any Person (other than the Purchaser
and its Representatives pursuant to this Agreement) relating to the acquisition of the Company or its Subsidiaries, or greater than 20%
of their businesses (whether by merger, stock sale, asset sale, tender offer, exchange offer or otherwise), or relating to the issuance
of equity (other than Common Stock as incentive compensation), (collectively, the matters described in this Section 5.2(i),
an “Acquisition Proposal” (ii) the Company shall, and shall instruct its Affiliates and Representatives to, immediately
cease and cause to be terminated all existing discussions or negotiations with any third party (other than the Purchaser and its Representatives
relating to this Agreement) conducted by or on behalf of the Company or any of its Subsidiaries on or prior to the date hereof in connection
with any other transaction relating to an Acquisition Proposal and (iii) the Company shall promptly inform the Purchaser in the
event that the Company or any of its Affiliates or Representatives receives any inquiry, proposal or offer that could reasonably be expected
to lead to an Acquisition Proposal.

 

Section 5.3     [Reserved].

 

Section 5.4     Stockholder
Approval.

 

(a)            [Reserved].

 

(b)            As
promptly as practicable after the date hereof, the Company shall take all action necessary under applicable Law to call, give notice of,
convene and hold a meeting of the stockholders of the Company for the purpose of obtaining the Stockholder Approval (the “Company
Stockholders’ Meeting”). The Company will convene and hold the Company Stockholders’ Meeting no later than the thirtieth
(30th) day following the mailing of the Proxy Statement to the Company’s stockholders. The Company shall take reasonable measures
to ensure that all proxies solicited in connection with the Company Stockholders’ Meeting are solicited in compliance with all applicable
Law. Notwithstanding anything to the contrary contained herein, if on the date of the Company Stockholders’ Meeting, or a date preceding
the date on which the Company Stockholders’ Meeting is scheduled, the Company reasonably believes that (i) it will not receive
proxies sufficient to obtain the Stockholder Approval, whether or not a quorum would be present or (ii) it will not have sufficient
shares of Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Company
Stockholders’ Meeting, the Company may postpone or adjourn, or make one or more successive postponements or adjournments of, the
Company Stockholders’ Meeting as long as the date of the Company Stockholders’ Meeting is not postponed or adjourned more
than an aggregate of thirty (30) calendar days in connection with any postponements or adjournments.

 

     32

     

    

 

(c)            As
promptly as reasonably practicable after the date hereof, the Company shall prepare and file with the SEC a preliminary proxy statement
(as amended and supplemented, the “Proxy Statement”), relating to the Company Stockholders’ Meeting. The Company
shall include in the Proxy Statement the recommendation of the Board that the stockholders of the Company vote in favor of the adoption
and approval of this Agreement and the transactions contemplated herein and in the other Definitive Documents (to the extent applicable).
The Company shall use its reasonable best efforts to obtain the Stockholder Approval, including using reasonable best efforts to solicit
proxies from the Company’s stockholders. The Company shall cause the Proxy Statement to be distributed to the Company’s stockholders
as promptly as practicable after the date the SEC confirms it has no further comments to the Proxy Statement. The Company will cause the
Proxy Statement to comply as to form in all material respects with the applicable requirements of the 1934 Act and the rules of the
SEC and NYSE American. The Company shall not file the Proxy Statement without providing Purchaser a reasonable opportunity to review and
comment thereon (which comments shall be reasonably considered by the Company). The Company shall resolve all SEC comments with respect
to the Proxy Statement as promptly as practicable after receipt thereof and cause the Proxy Statement in definitive form to be cleared
by the SEC and mailed (if required by applicable Law) to the Company’s stockholders as promptly as reasonably practicable following
filing with the SEC. The Company, prior to responding to SEC comments with respect to the Proxy Statement, will first provide Purchaser
and its Representatives a reasonable opportunity to review and comment thereon, and the Company will give due consideration to all reasonable
additions, deletions or changes suggested thereto by Purchaser or its Representatives.

 

(d)            Nothing
contained in this Agreement shall prohibit the Company or the Board from (i) complying with Rules 14d-9 and 14e-2(a) promulgated
under the 1934 Act, or (ii) issuing a “stop, look and listen” communication or similar communication of the type contemplated
by Section 14d-9(f) under the 1934 Act, or (iii) otherwise making any disclosure to the Company stockholders; provided
however, that in the case of the foregoing clause (iii) the Board determines in good faith, after consultation with its outside legal
counsel, that failure to make such disclosure would be inconsistent with its fiduciary duties under applicable Law.

 

Section 5.5     Registration
Rights Agreement. Simultaneously with the First Closing, the Company shall enter into a Registration Rights Agreement with the Purchaser,
in substantially the form attached hereto as Exhibit C (the “Registration Rights Agreement”).

 

Section 5.6     Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities
for purposes of the rules and regulations of the NYSE American such that it would require stockholder approval prior to the closing
of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.

 

     33

     

    

 

Section 5.7     Required
Minimum.

 

(a)            The
Company shall maintain a reserve of the Required Minimum from its duly authorized shares of Common Stock for issuance pursuant to this
Agreement and in connection with the exercise of the 2020 Warrants and 2021 Warrants, in such amount as may then be required to fulfill
its obligations in full under this Agreement, the 2020 Purchase Agreement, and the 2021 Purchase Agreements, without regard to any conversion
or exercise limits herein or therein.

 

(b)            If,
on any date, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock is less than 130% of (i) the
Required Minimum on such date, minus (ii) the number of shares of Common Stock previously issued pursuant to this Agreement, the
2020 Purchase Agreement and the 2021 Purchase Agreements, then the Board of Directors shall use reasonable best efforts to amend the Certificate
of Incorporation to increase the number of authorized but unissued shares of Common Stock to increase the number of authorized but unissued
shares of Common Stock to at least 130% of the Required Minimum at such time (minus the number of shares of Common Stock previously issued
pursuant to the Transaction Documents, the 2020 Purchase Agreement or the 2021 Purchase Agreements), as soon as reasonably practicable
and in any event not later than the 30th day after such date, provided that the Company will not be required at any time to authorize
a number of shares of Common Stock greater than the maximum remaining number of shares of Common Stock that could possibly be issued after
such time pursuant to this Agreement, the 2020 Purchase Agreement or the 2021 Purchase Agreements.

 

(c)            The
Company shall (i) in the time and manner required by the NYSE American, prepare and file with the NYSE American a Supplemental Listing
Application covering a number of shares of Common Stock at least equal to the Required Minimum on the date of such application, (ii) take
all steps necessary to cause such shares of Common Stock to be approved for listing or quotation on NYSE American as soon as possible
thereafter, (iii) provide to the Purchaser evidence of such listing or quotation and (iv) maintain the listing or quotation
of such Common Stock on any date at least equal to the Required Minimum on such date on NYSE American. The Company agrees to maintain
the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation,
including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation
in connection with such electronic transfer.

 

Section 5.8     Acknowledgment
of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common
Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under
the Definitive Documents, including, without limitation, its obligation to issue the Securities pursuant to this Agreement, are unconditional
and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution
or any claim the Company may have against Purchaser and regardless of the dilutive effect that such issuance may have on the ownership
of the other stockholders of the Company.

 

Section 5.9     Expense
Reimbursement. Upon either or both of the First Closing or the Second Closing, the Company shall promptly, upon written request of the
Purchaser, reimburse the Purchaser for all reasonable and documented fees and expenses of the Purchaser and its Affiliates and Representatives
(including the fees and expenses of counsel) incurred prior to, on or after the date hereof in connection with the examination, review,
due diligence investigation, documentation, negotiation, closing and funding of the transactions contemplated by this Agreement. Notwithstanding
anything to the contrary herein, this Section 5.9 shall survive the termination of this Agreement.

 

     34

     

    

 

Section 5.10     Blue
Sky Filings. The Company has taken or shall take, as applicable, such action as the Company shall reasonably determine is necessary in
order to obtain an exemption for, or to qualify the Securities for, sale to the Purchaser at the First Closing or Second Closing, as
applicable, under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence
of such actions promptly upon request of any Purchaser.

 

Article VI

 

CONDITIONS TO THE OBLIGATIONS OF THE PARTIES

 

Section 6.1     Conditions
to the Obligations of the Purchaser at the Second Closing. The obligations of Purchaser to consummate the Second Closing shall be subject
to (unless waived in writing by the Purchaser) the satisfaction of the following conditions prior to or at the Second Closing:

 

(a)            Material
Adverse Effect. Since the date of this Agreement, there shall not have occurred a Material Adverse Effect.

 

(b)            Governmental
Approvals. All authorizations, approvals, consents or clearances under applicable Law required in connection with the transactions
contemplated by this Agreement shall have been obtained or filed.

 

(c)            No
Legal Impediment to Issuance. No applicable Law will have been enacted or made effective and no Order will have been issued, promulgated,
enforced or made that serves to restrain, enjoin, make illegal or prohibit the timely consummation of the transactions contemplated by
this Agreement, and no action by a Governmental Entity will have been commenced and be continuing that seeks to restrain, enjoin, make
illegal or prohibit the timely consummation of the transactions contemplated by this Agreement.

 

(d)            Accuracy
of the Representations and Warranties. (i) The Fundamental Representations shall be true and correct in all respects as of the
date hereof and as of the Second Closing as though made at and as of the Second Closing (other than such representations and warranties
as are made as of an earlier date, which shall be so true and correct as of such earlier date) and (ii) the other representations
and warranties of the Company (A) that are qualified by “materiality”, “Material Adverse Effect” or similar
qualifier shall be true and correct in all respects as of the date hereof and as of the Second Closing as though made at and as of the
Second Closing (other than such representations and warranties as are made as of an earlier date, which shall be so true and correct as
of such earlier date) and (B) that are not qualified by “materiality”, “Material Adverse Effect” or similar
qualifier shall be true and correct in all material respects as of the date hereof and as of the Second Closing as though made at and
as of the Second Closing (other than such representations and warranties as are made as of an earlier date, which shall be so true and
correct as of such earlier date).

 

     35

     

    

 

(e)            Compliance
with Covenants. The Company shall have performed and complied, in all material respects, with all of its covenants and agreements
contained in this Agreement that contemplate, by their terms, performance or compliance prior to the Second Closing.

 

(f)            Delivery
of the Closing Certificate. The Company shall have delivered to Purchaser a certificate duly executed by the Chief Executive Officer
of the Company certifying that the conditions set forth in clauses (a), (d) and (e) of this Section 6.1 have been
fully satisfied.

 

(g)            Suspension.
Since the date hereof, trading in the Common Stock shall not have been suspended.

 

(h)            Stockholder
Approval. The Stockholder Approval shall have been duly received.

 

(i)            Other
Deliverables and Actions. The Company shall have delivered or caused to be delivered and shall have taken each of the actions contemplated
by Section 2.3.

 

Section 6.2     Conditions
to the Obligations of the Company at the Second Closing. The obligations of the Company to consummate the Second Closing shall be subject
to (unless waived in writing by the Company) the satisfaction of each of the following conditions prior to or at the Second Closing:

 

(a)            Governmental
Approvals. All authorizations, approvals, consents or clearances under applicable Law required in connection with the transactions
contemplated by this Agreement shall have been obtained or filed.

 

(b)            No
Legal Impediment to Issuance. No applicable Law will have been enacted or made effective and no Order will have been issued, promulgated,
enforced or made that serves to restrain, enjoin, make illegal or prohibit the consummation of the transactions contemplated by this Agreement,
and no action by a Governmental Entity will have been commenced and be continuing that seeks to restrain, enjoin, make illegal or prohibit
the consummation of the transactions contemplated by this Agreement.

 

(c)            Accuracy
of the Representations and Warranties. The representations and warranties of the Purchaser shall be true and correct in all respects
as of the date hereof and as of the Second Closing as though made at and as of the Second Closing (other than such representations and
warranties as are made as of an earlier date, which shall be so true and correct as of such earlier date) except, in each case, as would
not reasonably be expected, individually or in the aggregate, to prohibit or materially and adversely impact Purchaser’s performance
of its obligations under this Agreement.

 

     36

     

    

 

Article VII

 

TERMINATION

 

Section 7.1     Termination.
This Agreement may be terminated, and the transactions contemplated hereby may be abandoned, at any time prior to the First Closing:

 

(a)            by
mutual written consent of the Company and the Purchaser;

 

(b)            by
the Company or the Purchaser, upon written notice to the other Party, if a Governmental Entity of competent jurisdiction has issued an
Order or has taken any other action permanently enjoining or otherwise prohibiting the consummation of the transactions contemplated by
this Agreement, and such Order or action has become final and non-appealable; provided, however, that the right to terminate
this Agreement pursuant to this Section 7.1(b) shall not be available to any Party whose breach of any representation,
warranty, covenant or other agreement contained in this Agreement is the primary cause of the failure to avoid such Order or other action;
or

 

(c)            by
Purchaser, upon written notice to the Company, if:

 

(i)            (A) the
Company has breached any representation, warranty, covenant or other agreement made by the Company in this Agreement or such representation
or warranty shall have become inaccurate and such breach or inaccuracy would, individually or in the aggregate, cause a condition to the
Second Closing to not be able to be satisfied, (B) the Purchaser shall have delivered written notice of such breach or inaccuracy
to the Company and (C) such breach or inaccuracy is not cured by the Company before the 10th day following the delivery
of such notice; or

 

(ii)            the
Company or any of its direct or indirect Subsidiaries (A) voluntarily commences any case or files any petition seeking bankruptcy,
winding up, dissolution, liquidation, administration, moratorium, reorganization or other relief under any federal, state or foreign bankruptcy,
insolvency, administrative receivership or similar law now or hereafter in effect; (B) consents to the institution of, or fails to
contest in a timely and appropriate manner, any involuntary proceeding or petition described in the preceding subsection (A); (C) applies
for or consents to the appointment of a receiver, administrator, administrative receiver, trustee, custodian, sequestrator, conservator
or similar official with respect to the Company or any Affiliate or for a substantial part of the Company’s assets; (D) makes
a general assignment or arrangement for the benefit of creditors; or (E) takes any corporate action for the purpose of authorizing
any of the foregoing.

 

Section 7.2     Effect
of Termination. Upon termination of this Agreement pursuant to this Article VII, this Agreement shall forthwith become void
and there shall be no further obligations or liabilities on the part of the Parties; provided, that, Section 2.2(b)(iii),
Section 2.3(b)(ii), Section 5.9, Section 8.1, Section 8.3 through Section 8.9,
Section 8.11 and Section 8.13 shall survive the termination of this Agreement; provided further that nothing
set forth in this Agreement shall relieve any Party from liability for any breach of this Agreement occurring prior to such termination.

 

     37

     

    

 

Section 7.3     [Reserved].

 

Section 7.4     Second
Closing Abandonment. In the event that the Second Closing shall not have been consummated on or prior to 5:00 pm New York Time on May 15,
2022 or such later date, if any, as the Company and the Purchaser may mutually agree (the “Abandonment Date”), either
the Purchaser or the Company shall be entitled to deliver written notice (a “Second Closing Abandonment Notice”) to
the other specifying that the noticing party has elected not to proceed with the consummation of the Second Closing; provided, however,
that the right to deliver a Second Closing Abandonment Notice pursuant to this Section 7.4 shall not be available to any
Party whose breach of any representation, warranty, covenant or other agreement contained in this Agreement is the primary cause of the
failure of the Second Closing to occur on or prior to the Abandonment Date. Upon delivery of a Second Closing Abandonment Notice, the
obligation of each party to consummate the Second Closing shall terminate and no party shall thereafter be required to take any action
contemplated herein necessary to cause the Second Closing to occur (the “Second Closing Abandonment”). For the avoidance
of doubt, (i) the occurrence of the Second Closing Abandonment shall not limit any liability for a breach of this Agreement occurring
prior to the Second Closing Abandonment and (ii) following the Second Closing Abandonment, all other terms, conditions and indemnities
set forth herein shall continue in full effect in accordance with their terms.

 

Article VIII

 

GENERAL
PROVISIONS

 

Section 8.1     Notices.
All notices and other communications in connection with this Agreement shall be in writing and shall be deemed given if delivered personally,
sent via electronic mail (with confirmation), mailed by registered or certified mail (return receipt requested) or delivered by an express
courier (with confirmation) to the Parties at the following addresses (or at such other address for a Party as may be specified by like
notice):

 

(a)            If
to the Company:

 

Armata Pharmaceuticals, Inc.

4503 Glencoe Avenue

Marina del Rey, CA

Attn:     Chief
Executive Officer

Email:     info@armatapharma.com

 

with
a copy (which shall not constitute notice) to:

 

Thompson Hine LLP

335 Madison Avenue

12th Floor

New York, New York 10017-4611

Attn: Faith L. Charles

Email: faith.charles@thompsonhine.com  

 

     38

     

    

 

(b)            If
to the Purchaser:

 

c/o Innoviva

1350 Old Bayshore Highway Suite 400

Burlingame, CA 94010

Attention: Chief Executive Officer

Email: pavel.raifeld@inva.com

 

with a copy (which shall not constitute notice) to:

 

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019

Attention: Jared Fertman

Email: jfertman@willkie.com

 

Section 8.2     Assignment;
Third Party Beneficiaries. Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned
or transferred (in whole or in part) by any Party (whether by operation of law or otherwise) without the prior written consent of the
other Party; provided that Purchaser shall be entitled to assign this Agreement in whole or in part to any of its Subsidiaries or Affiliates.
Any purported assignment or transfer in violation of this Section 8.2 shall be null and void ab initio. This Agreement
(including the documents and instruments referred to in this Agreement) is not intended to and does not confer upon any Person any rights
or remedies under this Agreement other than the Parties.

 

Section 8.3     Prior
Negotiations; Entire Agreement. This Agreement (including the agreements attached as Schedules and Exhibits to and the documents
and instruments referred to in this Agreement, including the Definitive Documents) constitute the entire agreement of the Parties and
supersede all prior agreements, arrangements or understandings, whether written or oral, among the Parties with respect to the subject
matter of this Agreement.

 

Section 8.4     Governing
Law; Venue: Forum. THIS AGREEMENT (AND ANY CLAIMS OR CAUSE OF ACTION ARISING UNDER, OUT OF OR IN CONNECTION WITH THIS AGREEMENT, WHETHER
IN CONTRACT, TORT OR STATUTE) SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE APPLICABLE TO CONTRACTS
MADE AND TO BE PERFORMED IN SUCH STATE, WITHOUT GIVING EFFECT TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. Each of the Parties irrevocably
and unconditionally agrees that, subject to the immediately following sentence of this Section 8.4, any legal action, suit
or proceeding against it with respect to any matter arising under, out of or in connection with this Agreement or for recognition or
enforcement of any judgment rendered in any such action, suit or proceeding, may be brought in the Delaware Chancery Court (or, if the
Delaware Chancery Court shall be unavailable, then any federal court of the United States of America sitting in the State of Delaware),
and by execution and delivery of this Agreement, each of the Parties: (a) irrevocably submits itself to the nonexclusive jurisdiction
of such court, (b) waives any objection to laying venue in any such action, suit or proceeding and (c) waives any objection
that such court is an inconvenient forum or does not have jurisdiction over such Party.

 

     39

     

    

 

Section 8.5     Waiver
of Jury Trial. EACH PARTY IRREVOCABLY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING UNDER, OUT OF OR IN CONNECTION
WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER IN CONTRACT, TORT OR STATUTE).

 

Section 8.6     Counterparts.
This Agreement may be executed in any number of counterparts, all of which will be considered one and the same agreement and will become
effective when counterparts have been signed by each of the Parties and delivered to each other Party (including via facsimile or other
electronic transmission), it being understood that each Party need not sign the same counterpart.

 

Section 8.7     Waivers
and Amendments; Rights Cumulative; Consent; Severability.

 

(a)            This
Agreement may be amended, restated, modified or changed only by a written instrument signed by the Company and the Purchaser.

 

(b)            Unless
otherwise expressly set forth herein, the terms and conditions of this Agreement may be waived (i) by the Company only by a written
instrument executed by the Company and (ii) by the Purchaser only by a written instrument executed by the Purchaser. No delay on
the part of any Party in exercising any right, power or privilege pursuant to this Agreement will operate as a waiver thereof, nor will
any waiver on the part of any Party of any right, power or privilege pursuant to this Agreement, nor will any single or partial exercise
of any right, power or privilege pursuant to this Agreement, preclude any other or further exercise thereof or the exercise of any other
right, power or privilege pursuant to this Agreement.

 

(c)            In
the event that any provision hereof would be invalid or unenforceable in any respect under applicable Law, such provision shall be construed
by modifying or limiting it so as to be valid and enforceable to the maximum extent compatible with, and possible under, applicable Law.
The provisions hereof are severable, and in the event any provision hereof should be held invalid or unenforceable in any respect, it
shall not invalidate, render unenforceable or otherwise affect any other provision hereof.

 

Section 8.8     Headings;
Interpretation. The headings in this Agreement are for reference purposes only and will not in any way affect the meaning or interpretation
of this Agreement. Each Party participated in the drafting of this Agreement and this Agreement shall be construed without regard to
any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument
to be drafted.

 

Section 8.9     Specific
Performance. It is understood and agreed by the Parties that irreparable damage would occur if any provision of this Agreement were not
performed in accordance with the terms hereof and that the Parties shall be entitled to an injunction or injunctions without the necessity
of posting a bond to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof,
in addition to any other remedy to which they are entitled at law or in equity. Unless otherwise expressly stated in this Agreement,
no right or remedy described or provided in this Agreement is intended to be exclusive or to preclude a Party from pursuing other rights
and remedies to the extent available under this Agreement, at law or in equity.

 

     40

     

    

 

Section 8.10     Publicity.
The Parties shall jointly issue a press release disclosing the material terms of the transactions contemplated by this Agreement and
the other Definitive Documents in form and substance reasonably satisfactory to each Party by 9:30 a.m. New York time on the Business
Day immediately following the date hereof. The Company shall file a Current Report on Form 8-K with the SEC within the time required
by the 1934 Act in form and substance reasonably satisfactory to Purchaser. The Company shall consult with the Purchaser in issuing any
other press releases with respect to the transactions contemplated hereby, and the Company shall not issue any such press release or
otherwise make any such public statement without the prior consent of the Purchaser, except if such disclosure is required by Law, in
which case the Company shall promptly provide Purchaser with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of Purchaser, or include the name of Purchaser in any filing with the
SEC or any Governmental Entity, without the prior written consent of Purchaser, except to the extent such disclosure is required by Law
or NYSE American regulations, in which case the Company shall provide the Purchaser with prior notice of such disclosure.

 

Section 8.11     No
Recourse. Notwithstanding anything that may be expressed or implied in this Agreement, each Party covenants, agrees and acknowledges
that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against
any Party’s Affiliates, Related Parties or Representatives or any of such Party’s Affiliates’ or Related Parties’
Affiliates or Representatives in each case other than the Parties to this Agreement and each of their respective successors and permitted
assigns under this Agreement, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any
applicable Law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise
be incurred by any of the Related Parties or Representatives, as such, for any obligation or liability of any Party under this Agreement
or any documents or instruments delivered in connection herewith for any claim based on, in respect of or by reason of such obligations
or liabilities or their creation; provided, however, that nothing in this Section 8.11 shall relieve or otherwise
limit the liability of any Party hereto or any of their respective successors or permitted assigns for any breach or violation of its
obligations under this Agreement or such other documents or instruments. For the avoidance of doubt, none of the Parties will have any
recourse, be entitled to commence any proceeding or make any claim under this Agreement or in connection with the transactions contemplated
hereby except against any of the Parties or their respective successors and permitted assigns, as applicable.

 

Section 8.12     Further
Assurances. From and after the Second Closing Date, upon the reasonable request of any Party hereto, any other Party hereto shall execute,
acknowledge, file and/or deliver all such additional instruments, agreements and other documents, and shall do (or cause to be done)
all such additional acts and things, that are necessary, proper, advisable or desirable to carry out, consummate and make effective any
of the transactions contemplated by this Agreement.

 

     41

     

    

 

Section 8.13     Survival.
All covenants and other agreements contained in this Agreement which by their terms are to be performed following the Second Closing
shall survive the Second Closing until fully performed. The representations and warranties made in this Agreement shall survive as follows:
(a) the representations and warranties set forth in Section 3.1 (Organization and Qualification), Section 3.2
(Authorization; Enforcement Validity), Section 3.3 (Issuance of Securities), Section 3.13 (Transactions
with Affiliates), Section 3.14 (Capitalization) and Section 3.36 (Disclosure) (collectively,
the “Fundamental Representations”) shall survive indefinitely, (b) the representations and warranties in Section 3.19,
(Employee Relations), Section 3.23 (Tax Status) and Section 3.29 (ERISA Compliance) shall
survive until the expiration of the statute of limitations plus sixty (60) days and (c) all other representations and warranties
shall survive until the twelve (12)-month anniversary of the Second Closing.

 

[Remainder of Page Intentionally Left Blank]

 

     42

     

    

 

IN WITNESS WHEREOF, the undersigned
Parties have duly executed this Agreement as of the date first above written.

 

	 	Armata Pharmaceuticals, Inc.
	 	 
	 	By:	/s/ Brian Varnum
	 	 	Name: Brian Varnum
	 	 	Title: Chief Executive Officer

 

[Signature
Page to Securities Purchase Agreement]

 

     

     

    

 

	 	INNOVIVA STRATEGIC OPPORTUNITIES LLC
	 	 
	 	By: Innoviva, Inc. (its manager)
	 	 
	 	By:	/s/ Pavel Raifeld
	 	 	Name: Pavel Raifeld
	 	 	Title: Chief Executive Officer

 

[Signature
Page to Securities Purchase Agreement]

 

     

     

    

 

Exhibit A

 

Voting Agreement

 

(See attached.)

 

     

     

    

 

Exhibit B

 

Warrant Certificate

 

(See attached.)

 

     

     

    

 

Exhibit C

 

Registration Rights Agreement

 

(See attached.)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]